1. A compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein:

X is Cl, Br, CH3, CF3, CN, OCH3, ethyl, cyclopropyl, SCH3, or isopropyl;

A is a group having a formula selected from (A-1), (A-2), and (A-3):

Y¹, Y², and Y³ are each independently selected from O, S, NR^Y, C(=O), C(=O)O, C(=O)NR^Y, S(=O), S(=O)2, S(=O)NR^Y, S(=O)2NR^Y or NR^YC(=O)NR^Y, wherein each R^Y is independently H or C_1-4 alkyl;

L is C1-3 alkylene, O, S, NR^Y, C(=O), C(=O)O, C(=O)NR^Y, S(=O), S(=O)NR^Y, or NR^YC(=O)NR^Y;

Z is H, Cy^Z, halo, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, CN, NO₂, OR^a, SR^a, C(O)R^b, C(O)NR^cR^d, C(O)OR^a, OC(O)R^b, OC(O)NR^cR^d, NR^cR^d, NR^cC(O)R^b, NR^cC(O)OR^a, NR^cC(O)NR^cR^d, C(=NR^e)R^b, C(=NR^e)NR^cR^d, NR^cC(=NR^e)NR^cR^d, NR^cS(O)R^b, NR^cS(O)2R^b, NR^cS(O)2NR^cR^d, S(O)R^b, S(O)NR^cR^d, S(O)2R^b, and S(O)2NR^cR^d; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, and C_1-6 haloalkyl of Z are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Cy^Z, halo, CN, NO2, OR^a, SR^a, C(O)R^b, C(O)NR^cR^d, C(O)OR^a, OC(O)R^b, OC(O)NR^cR^d, C(=NR^e)NR^cR^d, NR^cC(=NR^e)NR^cR^d, NR^cR^d, NR^cC(O)R^b, NR^cC(O)OR^a, NR^cC(O)NR^cR^d, NR^cS(O)R^b, NR^cS(O)₂R^b, NR^cS(O)₂NR^cR^d, S(O)R^b, S(O)NR^cR^d, S(O)₂R^b, and S(O)₂NR^cR^d;

Cy^Z is selected from C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO₂, OR^a1, SR^a1, C(O)R^b1, C(O)NR^c1R^d1, C(O)OR^a1, OC(O)R^b1, OC(O)NR^c1R^d1,

C(=NR^e1)NR^c1R^d1, NR^c1C(=NR^e1)NR^c1R^d1, NR^c1R^d1, NR^c1C(O)R^b1, NR^c1C(O)OR^a1, NR^c1C(O)NR^c1R^d1, NR^c1S(O)R^b1, NR^c1S(O)₂R^b1, NR^c1S(O)₂NR^c1R^d1, S(O)R^b1, S(O)NR^c1R^d1, S(O)2R^b1, and S(O)2NR^c1R^d1, wherein the alkyl, C2-6 alkenyl, and C2-6 alkynyl are optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO2, OR^a1, SR^a1, C(O)R^b1, C(O)NR^c1R^d1, C(O)OR^a1, OC(O)R^b1, OC(O)NR^c1R^d1, C(=NR^e1)NR^c1R^d1, NR^c1C(=NR^e1)NR^c1R^d1, NR^c1R^d1, NR^c1C(O)R^b1, NR^c1C(O)OR^a1, NR^c1C(O)NR^c1R^d1, NR^c1S(O)R^b1, NR^c1S(O)₂R^b1, NR^c1S(O)₂NR^c1R^d1, S(O)R^b1, S(O)NR^c1R^d1, S(O)₂R^b1, and S(O)2NR^c1R^d1;

Ring D is a monocyclic or polycyclic 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 groups independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, CN, NO₂, OR^a2, SR^a2, C(O)R^b2, C(O)NR^c2R^d2,

C(O)OR^a2, OC(O)R^b2, OC(O)NR^c2R^d2, C(=NR^e2)NR^c2R^d2, NR^c2C(=NR^e2)NR^c2R^d2, NR^c2R^d2, NR^c2C(O)R^b2, NR^c2C(O)OR^a2, NR^c2C(O)NR^c2R^d2, NR^c2S(O)R^b2, NR^c2S(O)₂R^b2,

NR^c2S(O)2NR^c2R^d2, S(O)R^b2, S(O)NR^c2R^d2, S(O)2R^b2, and S(O)2NR^c2R^d2, wherein the C1-6 alkyl, C_2-6 alkenyl, and C_2-6 alkynyl are each optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, NO2, OR^a2, SR^a2, C(O)R^b2, C(O)NR^c2R^d2, C(O)OR^a2, OC(O)R^b2, OC(O)NR^c2R^d2, C(=NR^e2)NR^c2R^d2, NR^c2C(=NR^e2)NR^c2R^d2, NR^c2R^d2,

NR^c2C(O)R^b2, NR^c2C(O)OR^a2, NR^c2C(O)NR^c2R^d2, NR^c2S(O)R^b2, NR^c2S(O)2R^b2,

NR^c2S(O)₂NR^c2R^d2, S(O)R^b2, S(O)NR^c2R^d2, S(O)₂R^b2, and S(O)₂NR^c2R^d2;

R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, and R¹² are each independently selected from H, halo, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_6-10 aryl, C_3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl- C_1-4 alkyl, CN, NO₂, OR^a3, SR^a3, C(O)R^b3, C(O)NR^c3R^d3, C(O)OR^a3, OC(O)R^b3, OC(O)NR^c3R^d3, NR^c3R^d3, NR^c3C(O)R^b3, NR^c3C(O)OR^a3, NR^c3C(O)NR^c3R^d3, C(=NR^e3)R^b3, C(=NR^e3)NR^c3R^d3, NR^c3C(=NR^e3)NR^c3R^d3, NR^c3S(O)R^b3, NR^c3S(O)₂R^b3, NR^c3S(O)₂NR^c3R^d3, S(O)R^b3, S(O)NR^c3R^d3, S(O)2R^b3, and S(O)2NR^c3R^d3; wherein said C1-6 alkyl, C2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_6-10 aryl, C_3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C_1-4 alkyl, and 4-10 membered heterocycloalkyl-C_1-4 alkyl of said R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, and R¹² are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, CN, NO2, OR^a3, SR^a3, C(O)R^b3, C(O)NR^c3R^d3, C(O)OR^a3, OC(O)R^b3,

OC(O)NR^c3R^d3, NR^c3R^d3, NR^c3C(O)R^b3, NR^c3C(O)OR^a3, NR^c3C(O)NR^c3R^d3, C(=NR^e3)R^b3, C(=NR^e3)NR^c3R^d3, NR^c3C(=NR^e3)NR^c3R^d3, NR^c3S(O)R^b3, NR^c3S(O)2R^b3, NR^c3S(O)2NR^c3R^d3, S(O)R^b3, S(O)NR^c3R^d3, S(O)₂R^b3, and S(O)₂NR^c3R^d3;

or R¹ and R³ together with the carbon atoms to which they are attached form a C5-10 cycloalkyl ring or a 5-10 membered heterocycloalkyl ring, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO2, OR^a3, SR^a3, C(O)R^b3, C(O)NR^c3R^d3, C(O)OR^a3, OC(O)R^b3, OC(O)NR^c3R^d3, NR^c3R^d3, NR^c3C(O)R^b3, NR^c3C(O)OR^a3, NR^c3C(O)NR^c3R^d3, C(=NR^e3)R^b3, C(=NR^e3)NR^c3R^d3, NR^c3C(=NR^e3)NR^c3R^d3, NR^c3S(O)R^b3, NR^c3S(O)2R^b3, NR^c3S(O)2NR^c3R^d3, S(O)R^b3, S(O)NR^c3R^d3, S(O)₂R^b3, and S(O)₂NR^c3R^d3;

or R³ and R⁵ together with the carbon atoms to which they are attached form a C5-10 cycloalkyl ring or a 5-10 membered heterocycloalkyl ring, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C_1-6 haloalkyl, CN, NO₂, OR^a3, SR^a3, C(O)R^b3, C(O)NR^c3R^d3, C(O)OR^a3, OC(O)R^b3, OC(O)NR^c3R^d3, NR^c3R^d3, NR^c3C(O)R^b3, NR^c3C(O)OR^a3, NR^c3C(O)NR^c3R^d3, C(=NR^e3)R^b3, C(=NR^e3)NR^c3R^d3, NR^c3C(=NR^e3)NR^c3R^d3, NR^c3S(O)R^b3, NR^c3S(O)₂R^b3, NR^c3S(O)₂NR^c3R^d3, S(O)R^b3, S(O)NR^c3R^d3, S(O)2R^b3, and S(O)2NR^c3R^d3;

or R⁷ and R⁹ together with the carbon atoms to which they are attached form a C_5-10 cycloalkyl ring or a 5-10 membered heterocycloalkyl ring, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C1-6 haloalkyl, CN, NO2, OR^a3, SR^a3, C(O)R^b3, C(O)NR^c3R^d3, C(O)OR^a3, OC(O)R^b3, OC(O)NR^c3R^d3, NR^c3R^d3, NR^c3C(O)R^b3, NR^c3C(O)OR^a3, NR^c3C(O)NR^c3R^d3, C(=NR^e3)R^b3, C(=NR^e3)NR^c3R^d3, NR^c3C(=NR^e3)NR^c3R^d3, NR^c3S(O)R^b3, NR^c3S(O)2R^b3, NR^c3S(O)2NR^c3R^d3, S(O)R^b3, S(O)NR^c3R^d3, S(O)2R^b3, and S(O)2NR^c3R^d3; or R⁹ and R¹¹ together with the carbon atoms to which they are attached form a C5-10 cycloalkyl ring or a 5-10 membered heterocycloalkyl ring, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C_1-6 haloalkyl, CN, NO₂, OR^a3, SR^a3, C(O)R^b3, C(O)NR^c3R^d3, C(O)OR^a3, OC(O)R^b3, OC(O)NR^c3R^d3, NR^c3R^d3, NR^c3C(O)R^b3, NR^c3C(O)OR^a3, NR^c3C(O)NR^c3R^d3, C(=NR^e3)R^b3, C(=NR^e3)NR^c3R^d3, NR^c3C(=NR^e3)NR^c3R^d3, NR^c3S(O)R^b3, NR^c3S(O)₂R^b3, NR^c3S(O)₂NR^c3R^d3, S(O)R^b3, S(O)NR^c3R^d3, S(O)2R^b3, and S(O)2NR^c3R^d3;

or R⁵ and R⁷ together with the carbon atoms to which they are attached and together with Y² form a 5-10 membered heterocycloalkyl ring optionally substituted with 1, 2, or 3 substituents independently selected from halo, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, CN, NO2, OR^a3, SR^a3, C(O)R^b3, C(O)NR^c3R^d3, C(O)OR^a3, OC(O)R^b3,

OC(O)NR^c3R^d3, NR^c3R^d3, NR^c3C(O)R^b3, NR^c3C(O)OR^a3, NR^c3C(O)NR^c3R^d3, C(=NR^e3)R^b3, C(=NR^e3)NR^c3R^d3, NR^c3C(=NR^e3)NR^c3R^d3, NR^c3S(O)R^b3, NR^c3S(O)2R^b3, NR^c3S(O)2NR^c3R^d3, S(O)R^b3, S(O)NR^c3R^d3, S(O)2R^b3, and S(O)2NR^c3R^d3;

or R¹ and R³ together form a double bond between the carbon atoms to which they are attached;

or R³ and R⁵ together form a double bond between the carbon atoms to which they are attached;

or R⁷ and R⁹ together form a double bond between the carbon atoms to which they are attached;

or R⁹ and R¹¹ together form a double bond between the carbon atoms to which they are attached;

or R⁹, R¹⁰, R¹¹, and R¹² together form a triple bond between the carbon atoms to which they are attached;

R¹³, R¹⁴, and R¹⁵ are each independently selected from H, halo, C_1-6 alkyl, C_2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4- 10 membered heterocycloalkyl, C_6-10 aryl-C_1-4 alkyl, C_3-7 cycloalkyl-C_1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl-C1-4 alkyl, CN, NO2, OR^a4, SR^a4, C(O)R^b4, C(O)NR^c4R^d4, C(O)OR^a4, OC(O)R^b4, OC(O)NR^c4R^d4, NR^c4R^d4, NR^c4C(O)R^b4, NR^c4C(O)OR^a4, NR^c4C(O)NR^c4R^d4, C(=NR^e4)R^b4, C(=NR^e4)NR^c4R^d4, NR^c4C(=NR^e4)NR^c4R^d4, NR^c4S(O)R^b4, NR^c4S(O)₂R^b4, NR^c4S(O)₂NR^c4R^d4, S(O)R^b4, S(O)NR^c4R^d4, S(O)₂R^b4, and S(O)2NR^c4R^d4; wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C_3-7 cycloalkyl-C_1-4 alkyl, 5-10 membered heteroaryl-C_1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl of said R¹³, R¹⁴, and R¹⁵ are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C1-6 haloalkyl, CN, NO2, OR^a4, SR^a4, C(O)R^b4, C(O)NR^c4R^d4, C(O)OR^a4, OC(O)R^b4, OC(O)NR^c4R^d4, NR^c4R^d4, NR^c4C(O)R^b4, NR^c4C(O)OR^a4, NR^c4C(O)NR^c4R^d4, C(=NR^e4)R^b4, C(=NR^e4)NR^c4R^d4, NR^c4C(=NR^e4)NR^c4R^d4, NR^c4S(O)R^b4, NR^c4S(O)2R^b4, NR^c4S(O)2NR^c4R^d4, S(O)R^b4, S(O)NR^c4R^d4, S(O)₂R^b4, and S(O)₂NR^c4R^d4;

Ring E is a mono- or polycyclic ring selected from C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl;

Q¹, Q², and Q³ are each a group of formula (B-1):

Y⁴, Y⁵, and Y⁶ are each independently selected from O, S, NR^Y, C(=O), C(=O)O, C(=O)NR^Y, S(=O), S(=O)2, S(=O)NR^Y, S(=O)2NR^Y or NR^YC(=O)NR^Y;

G¹ is–C(R^G)(R^H)– or a group of formula (C-1), (C-2), or (C-3):

G² is–C(R^I)(R^J)– or a group of formula (C-1), (C-2), or (C-3);

R^A, R^B, R^C, R^D, R^E, R^F, R^G, R^H, R^I, R^J, R^K, R^L, R^M, and R^N are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_6-10 aryl-C_1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered

heterocycloalkyl-C_1-4 alkyl, CN, NO₂, OR^a5, SR^a5, C(O)R^b5, C(O)NR^c5R^d5, C(O)OR^a5, OC(O)R^b5, OC(O)NR^c5R^d5, C(=NR^e5)NR^c5R^d5, NR^c5C(=NR^e5)NR^c5R^d5, NR^c5R^d5,

NR^c5C(O)R^b5, NR^c5C(O)OR^a5, NR^c5C(O)NR^c5R^d5, NR^c5S(O)R^b5, NR^c5S(O)₂R^b5,

NR^c5S(O)2NR^c5R^d5, S(O)R^b5, S(O)NR^c5R^d5, S(O)2R^b5, and S(O)2NR^c5R^d5; wherein said C1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_6-10 aryl, C_3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C_1-4 alkyl, and 4-10 membered heterocycloalkyl-C_1-4 alkyl of said R^A, R^B, R^C, R^D, R^E, R^F, R^G, R^H, R^I, R^J, R^K, R^L, R^M, and R^N are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C_1-6 alkyl, C_2-6 alkenyl, C_2- 6 alkynyl, C1-6 haloalkyl, CN, NO2, OR^a5, SR^a5, C(O)R^b5, C(O)NR^c5R^d5, C(O)OR^a5,

OC(O)R^b5, OC(O)NR^c5R^d5, C(=NR^e5)NR^c5R^d5, NR^c5C(=NR^e5)NR^c5R^d5, NR^c5R^d5,

NR^c5C(O)R^b5, NR^c5C(O)OR^a5, NR^c5C(O)NR^c5R^d5, NR^c5S(O)R^b5, NR^c5S(O)2R^b5,

NR^c5S(O)2NR^c5R^d5, S(O)R^b5, S(O)NR^c5R^d5, S(O)2R^b5, and S(O)2NR^c5R^d5;

or R^G and R^I together with the carbon atoms to which they are attached and together with Y⁵ form a 5-10 membered heterocycloalkyl ring optionally substituted with 1, 2, or 3 substituents independently selected from halo, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, CN, NO2, OR^a3, SR^a3, C(O)R^b3, C(O)NR^c3R^d3, C(O)OR^a3, OC(O)R^b3,

OC(O)NR^c3R^d3, NR^c3R^d3, NR^c3C(O)R^b3, NR^c3C(O)OR^a3, NR^c3C(O)NR^c3R^d3, C(=NR^e3)R^b3, C(=NR^e3)NR^c3R^d3, NR^c3C(=NR^e3)NR^c3R^d3, NR^c3S(O)R^b3, NR^c3S(O)2R^b3, NR^c3S(O)2NR^c3R^d3, S(O)R^b3, S(O)NR^c3R^d3, S(O)₂R^b3, and S(O)₂NR^c3R^d3;

or R^C and R^E together form a double bond between the carbon atoms to which they are attached;

or R^E and R^G together form a double bond between the carbon atoms to which they are attached;

or R^I and R^K together form a double bond between the carbon atoms to which they are attached;

or R^K and R^M together form a double bond between the carbon atoms to which they are attached;

or R^K, R^L, R^M, and R^N together form a triple bond between the carbon atoms to which they are attached;

D¹ and D² are each independently selected from N and CH;

D³, D⁴, D⁵, D⁶, D⁷, D⁸, and D⁹ are each independently selected from N and CR^X, wherein each R^X is independently selected from H, halo, and C_1-4 alkyl; D¹⁰ is O, S, NH or CH2;

Ring F is a mono- or polycyclic ring selected from C_6-10 aryl, C_3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 substituents independently selected from halo, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C1-6 haloalkyl, CN, NO2, OR^a6, SR^a6, C(O)R^b6, C(O)NR^c6R^d6, C(O)OR^a6, OC(O)R^b6, OC(O)NR^c6R^d6, C(=NR^e6)NR^c6R^d6, NR^c6C(=NR^e6)NR^c6R^d6, NR^c6R^d6, NR^c6C(O)R^b6, NR^c6C(O)OR^a6, NR^c6C(O)NR^c6R^d6, NR^c6S(O)R^b6, NR^c6S(O)2R^b6, NR^c6S(O)2NR^c6R^d6, S(O)R^b6, S(O)NR^c6R^d6, S(O)₂R^b6, and S(O)₂NR^c6R^d6, wherein the alkyl, C_2-6 alkenyl, and C_2-6 alkynyl are optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO₂, OR^a6, SR^a6, C(O)R^b6, C(O)NR^c6R^d6, C(O)OR^a6, OC(O)R^b6, OC(O)NR^c6R^d6, C(=NR^e6)NR^c6R^d6, NR^c6C(=NR^e6)NR^c6R^d6, NR^c6R^d6, NR^c6C(O)R^b6, NR^c6C(O)OR^a6, NR^c6C(O)NR^c6R^d6, NR^c6S(O)R^b6, NR^c6S(O)₂R^b6, NR^c6S(O)₂NR^c6R^d6, S(O)R^b6, S(O)NR^c6R^d6, S(O)2R^b6, and S(O)2NR^c6R^d6;

each R^a, R^b, R^c, R^d, R^a1, R^b1, R^c1, R^d1, R^a2, R^b2, R^c2, R^d2, R^a3, R^b3, R^c3, R^d3, R^a4, R^b4, R^c4, R^d4, R^a5, R^b5, R^c5, R^d5, R^a6, R^b6, R^c6, and R^d6 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_6-10 aryl-C_1-4 alkyl, C_3-7 cycloalkyl-C_1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl, wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_6-10 aryl, C_3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C_1-4 alkyl, and 4-10 membered heterocycloalkyl-C_1-4 alkyl of said R^a, R^b, R^c, R^d, R^a1, R^b1, R^c1, R^d1, R^a2, R^b2, R^c2, R^d2, R^a3, R^b3, R^c3, R^d3, R^a4, R^b4, R^c4, R^d4, R^a5, R^b5, R^c5, R^d5, R^a6, R^b6, R^c6, and R^d6 is optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, OR^a7, SR^a7, C(O)R^b7, C(O)NR^c7R^d7, C(O)OR^a7, OC(O)R^b7, OC(O)NR^c7R^d7, NR^c7R^d7, NR^c7C(O)R^b7, NR^c7C(O)NR^c7R^d7, NR^c7C(O)OR^a7, C(=NR^e7)NR^c7R^d7,

NR^c7C(=NR^e7)NR^c3R^d7, S(O)R^b7, S(O)NR^c7R^d7, S(O)₂R^b7, NR^c7S(O)₂R^b7, NR^c7S(O)₂NR^c7R^d7, and S(O)2NR^c7R^d7;

or R^c and R^d together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from CN, halo, C_1-4 alkyl, C_1-4 haloalkyl, C_1-6 haloalkyl, C_2-6 alkenyl, C2-6 alkynyl, CN, OR^a7, SR^a7, C(O)R^b7, C(O)NR^c7R^d7, C(O)OR^a7, OC(O)R^b7, OC(O)NR^c7R^d7, NR^c7R^d7, NR^c7C(O)R^b7, NR^c7C(O)NR^c7R^d7, NR^c7C(O)OR^a7, C(=NR^e7)NR^c7R^d7, NR^c7C(=NR^e7)NR^c3R^d7, S(O)R^b7, S(O)NR^c7R^d7, S(O)2R^b7, NR^c7S(O)2R^b7, NR^c7S(O)2NR^c7R^d7, and S(O)₂NR^c7R^d7;

or R^c1 and R^d2 together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from CN, halo, C1-4 alkyl, C1-4 haloalkyl, C1-6 haloalkyl, C2-6 alkenyl, C_2-6 alkynyl, CN, OR^a7, SR^a7, C(O)R^b7, C(O)NR^c7R^d7, C(O)OR^a7, OC(O)R^b7, OC(O)NR^c7R^d7, NR^c7R^d7, NR^c7C(O)R^b7, NR^c7C(O)NR^c7R^d7, NR^c7C(O)OR^a7, C(=NR^e7)NR^c7R^d7,

NR^c7C(=NR^e7)NR^c3R^d7, S(O)R^b7, S(O)NR^c7R^d7, S(O)₂R^b7, NR^c7S(O)₂R^b7, NR^c7S(O)₂NR^c7R^d7, and S(O)2NR^c7R^d7;

or R^c2 and R^d2 together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from CN, halo, C_1-4 alkyl, C_1-4 haloalkyl, C_1-6 haloalkyl, C_2-6 alkenyl, C2-6 alkynyl, CN, OR^a7, SR^a7, C(O)R^b7, C(O)NR^c7R^d7, C(O)OR^a7, OC(O)R^b7, OC(O)NR^c7R^d7, NR^c7R^d7, NR^c7C(O)R^b7, NR^c7C(O)NR^c7R^d7, NR^c7C(O)OR^a7, C(=NR^e7)NR^c7R^d7,

NR^c7C(=NR^e7)NR^c3R^d7, S(O)R^b7, S(O)NR^c7R^d7, S(O)2R^b7, NR^c7S(O)2R^b7, NR^c7S(O)2NR^c7R^d7, and S(O)2NR^c7R^d7;

or R^c3 and R^d3 together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from CN, halo, C_1-4 alkyl, C_1-4 haloalkyl, C_1-6 haloalkyl, C_2-6 alkenyl, C2-6 alkynyl, CN, OR^a7, SR^a7, C(O)R^b7, C(O)NR^c7R^d7, C(O)OR^a7, OC(O)R^b7, OC(O)NR^c7R^d7, NR^c7R^d7, NR^c7C(O)R^b7, NR^c7C(O)NR^c7R^d7, NR^c7C(O)OR^a7, C(=NR^e7)NR^c7R^d7,

NR^c7C(=NR^e7)NR^c3R^d7, S(O)R^b7, S(O)NR^c7R^d7, S(O)2R^b7, NR^c7S(O)2R^b7, NR^c7S(O)2NR^c7R^d7, and S(O)₂NR^c7R^d7;

or R^c4 and R^d4 together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from CN, halo, C1-4 alkyl, C1-4 haloalkyl, C1-6 haloalkyl, C2-6 alkenyl, C_2-6 alkynyl, CN, OR^a7, SR^a7, C(O)R^b7, C(O)NR^c7R^d7, C(O)OR^a7, OC(O)R^b7, OC(O)NR^c7R^d7, NR^c7R^d7, NR^c7C(O)R^b7, NR^c7C(O)NR^c7R^d7, NR^c7C(O)OR^a7, C(=NR^e7)NR^c7R^d7,

NR^c7C(=NR^e7)NR^c3R^d7, S(O)R^b7, S(O)NR^c7R^d7, S(O)₂R^b7, NR^c7S(O)₂R^b7, NR^c7S(O)₂NR^c7R^d7, and S(O)2NR^c7R^d7;

or R^c5 and R^d5 together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from CN, halo, C1-4 alkyl, C1-4 haloalkyl, C1-6 haloalkyl, C2-6 alkenyl, C_2-6 alkynyl, CN, OR^a7, SR^a7, C(O)R^b7, C(O)NR^c7R^d7, C(O)OR^a7, OC(O)R^b7, OC(O)NR^c7R^d7, NR^c7R^d7, NR^c7C(O)R^b7, NR^c7C(O)NR^c7R^d7, NR^c7C(O)OR^a7, C(=NR^e7)NR^c7R^d7,

NR^c7C(=NR^e7)NR^c3R^d7, S(O)R^b7, S(O)NR^c7R^d7, S(O)₂R^b7, NR^c7S(O)₂R^b7, NR^c7S(O)₂NR^c7R^d7, and S(O)2NR^c7R^d7;

or R^c6 and R^d6 together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from CN, halo, C_1-4 alkyl, C_1-4 haloalkyl, C_1-6 haloalkyl, C_2-6 alkenyl, C2-6 alkynyl, CN, OR^a7, SR^a7, C(O)R^b7, C(O)NR^c7R^d7, C(O)OR^a7, OC(O)R^b7, OC(O)NR^c7R^d7, NR^c7R^d7, NR^c7C(O)R^b7, NR^c7C(O)NR^c7R^d7, NR^c7C(O)OR^a7, C(=NR^e7)NR^c7R^d7,

NR^c7C(=NR^e7)NR^c3R^d7, S(O)R^b7, S(O)NR^c7R^d7, S(O)2R^b7, NR^c7S(O)2R^b7, NR^c7S(O)2NR^c7R^d7, and S(O)₂NR^c7R^d7;

R^a7, R^b7, R^c7, and R^d7 are independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2- ₆ alkenyl, C_2-6 alkynyl, C_6-10 aryl, C_3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl, wherein said C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4- 10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C_1-4 alkyl, and 4-10 membered heterocycloalkyl-C_1-4 alkyl are each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C_1-6 alkyl, C_1-6 alkoxy, C_1-6 haloalkyl, and C_1-6 haloalkoxy;

each R^e, R^e1, R^e2, R^e3, R^e4, R^e5, R^e6 and R^e7 is independently selected from H, C1-4 alkyl, and CN;

a is 0 or 1;

b is 0, 1, 2, or 3;

c is 0, 1, or 2;

d is 0, 1, or 2;

m is 0 or 1;

n is 0 or 1;

p is 0 or 1;

q is 0 or 1;

r is 0 or 1;

s1 is 0, 1, or 2;

s2 is 0, 1, 2, or 3;

t1 is 0 or 1;

t2 is 0 or 1; t3 is 0 or 1;

u is 0, 1, 2, or 3;

v is 0 or 1; and

w is 0 or 1;

wherein any aforementioned heteroaryl or heterocycloalkyl group comprises 1, 2, 3, or 4 ring-forming heteroatoms independently selected from O, N, and S; and

wherein one or more ring-forming C or N atoms of any aforementioned heterocycloalkyl group is optionally substituted by an oxo (=O) group. 2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein A is the group having the formula A-1.

3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein:

X is Cl, Br, CH3, CF3, CN, OCH3, ethyl, cyclopropyl, SCH3, or isopropyl;

A is a group having the formula (A-1):

1)

Y¹, Y², and Y³ are each independently selected from O, S, NR^Y, C(=O), C(=O)O, C(=O)NR^Y, S(=O), S(=O)2, S(=O)NR^Y, S(=O)2NR^Y or NR^YC(=O)NR^Y, wherein each R^Y is independently H or C_1-4 alkyl;

L is C1-3 alkylene, O, S, NR^Y, C(=O), C(=O)O, C(=O)NR^Y, S(=O), S(=O)NR^Y, or NR^YC(=O)NR^Y;

Z is H, Cy^Z, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO2, OR^a, SR^a, C(O)R^b, C(O)NR^cR^d, C(O)OR^a, OC(O)R^b, OC(O)NR^cR^d, NR^cR^d, NR^cC(O)R^b,

NR^cC(O)OR^a, NR^cC(O)NR^cR^d, C(=NR^e)R^b, C(=NR^e)NR^cR^d, NR^cC(=NR^e)NR^cR^d,

NR^cS(O)R^b, NR^cS(O)₂R^b, NR^cS(O)₂NR^cR^d, S(O)R^b, S(O)NR^cR^d, S(O)₂R^b, and S(O)₂NR^cR^d; wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C1-6 haloalkyl of Z are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Cy^Z, halo, CN, NO₂, OR^a, SR^a, C(O)R^b, C(O)NR^cR^d, C(O)OR^a, OC(O)R^b, OC(O)NR^cR^d, C(=NR^e)NR^cR^d, NR^cC(=NR^e)NR^cR^d, NR^cR^d, NR^cC(O)R^b, NR^cC(O)OR^a, NR^cC(O)NR^cR^d, NR^cS(O)R^b, NR^cS(O)2R^b, NR^cS(O)2NR^cR^d, S(O)R^b, S(O)NR^cR^d, S(O)2R^b, and S(O)2NR^cR^d;

Cy^Z is selected from C_6-10 aryl, C_3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 substituents independently selected from halo, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, CN, NO2, OR^a1, SR^a1, C(O)R^b1, C(O)NR^c1R^d1, C(O)OR^a1, OC(O)R^b1, OC(O)NR^c1R^d1,

C(=NR^e1)NR^c1R^d1, NR^c1C(=NR^e1)NR^c1R^d1, NR^c1R^d1, NR^c1C(O)R^b1, NR^c1C(O)OR^a1, NR^c1C(O)NR^c1R^d1, NR^c1S(O)R^b1, NR^c1S(O)2R^b1, NR^c1S(O)2NR^c1R^d1, S(O)R^b1, S(O)NR^c1R^d1, S(O)₂R^b1, and S(O)₂NR^c1R^d1, wherein the alkyl, C_2-6 alkenyl, and C_2-6 alkynyl are optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO2, OR^a1, SR^a1, C(O)R^b1, C(O)NR^c1R^d1, C(O)OR^a1, OC(O)R^b1, OC(O)NR^c1R^d1, C(=NR^e1)NR^c1R^d1, NR^c1C(=NR^e1)NR^c1R^d1, NR^c1R^d1, NR^c1C(O)R^b1, NR^c1C(O)OR^a1, NR^c1C(O)NR^c1R^d1, NR^c1S(O)R^b1, NR^c1S(O)2R^b1, NR^c1S(O)2NR^c1R^d1, S(O)R^b1, S(O)NR^c1R^d1, S(O)2R^b1, and S(O)2NR^c1R^d1;

Ring D is a monocyclic or polycyclic 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 groups independently selected from halo, C_1-6 alkyl, C_2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO2, OR^a2, SR^a2, C(O)R^b2, C(O)NR^c2R^d2,

C(O)OR^a2, OC(O)R^b2, OC(O)NR^c2R^d2, C(=NR^e2)NR^c2R^d2, NR^c2C(=NR^e2)NR^c2R^d2, NR^c2R^d2, NR^c2C(O)R^b2, NR^c2C(O)OR^a2, NR^c2C(O)NR^c2R^d2, NR^c2S(O)R^b2, NR^c2S(O)2R^b2,

NR^c2S(O)₂NR^c2R^d2, S(O)R^b2, S(O)NR^c2R^d2, S(O)₂R^b2, and S(O)₂NR^c2R^d2, wherein the C_1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl are each optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, NO₂, OR^a2, SR^a2, C(O)R^b2, C(O)NR^c2R^d2, C(O)OR^a2, OC(O)R^b2, OC(O)NR^c2R^d2, C(=NR^e2)NR^c2R^d2, NR^c2C(=NR^e2)NR^c2R^d2, NR^c2R^d2,

NR^c2C(O)R^b2, NR^c2C(O)OR^a2, NR^c2C(O)NR^c2R^d2, NR^c2S(O)R^b2, NR^c2S(O)₂R^b2,

NR^c2S(O)2NR^c2R^d2, S(O)R^b2, S(O)NR^c2R^d2, S(O)2R^b2, and S(O)2NR^c2R^d2;

R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, and R¹² are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_6-10 aryl-C_1-4 alkyl, C_3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered heterocycloalkyl- C_1-4 alkyl, CN, NO₂, OR^a3, SR^a3, C(O)R^b3, C(O)NR^c3R^d3, C(O)OR^a3, OC(O)R^b3,

OC(O)NR^c3R^d3, NR^c3R^d3, NR^c3C(O)R^b3, NR^c3C(O)OR^a3, NR^c3C(O)NR^c3R^d3, C(=NR^e3)R^b3, C(=NR^e3)NR^c3R^d3, NR^c3C(=NR^e3)NR^c3R^d3, NR^c3S(O)R^b3, NR^c3S(O)2R^b3, NR^c3S(O)2NR^c3R^d3, S(O)R^b3, S(O)NR^c3R^d3, S(O)₂R^b3, and S(O)₂NR^c3R^d3; wherein said C_1-6 alkyl, C_2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_6-10 aryl-C_1-4 alkyl, C_3-7 cycloalkyl-C_1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl of said R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, and R¹² are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO₂, OR^a3, SR^a3, C(O)R^b3, C(O)NR^c3R^d3, C(O)OR^a3, OC(O)R^b3,

OC(O)NR^c3R^d3, NR^c3R^d3, NR^c3C(O)R^b3, NR^c3C(O)OR^a3, NR^c3C(O)NR^c3R^d3, C(=NR^e3)R^b3, C(=NR^e3)NR^c3R^d3, NR^c3C(=NR^e3)NR^c3R^d3, NR^c3S(O)R^b3, NR^c3S(O)₂R^b3, NR^c3S(O)₂NR^c3R^d3, S(O)R^b3, S(O)NR^c3R^d3, S(O)2R^b3, and S(O)2NR^c3R^d3;

or R¹ and R³ together with the carbon atoms to which they are attached form a C_5-10 cycloalkyl ring or a 5-10 membered heterocycloalkyl ring, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C1-6 haloalkyl, CN, NO2, OR^a3, SR^a3, C(O)R^b3, C(O)NR^c3R^d3, C(O)OR^a3, OC(O)R^b3, OC(O)NR^c3R^d3, NR^c3R^d3, NR^c3C(O)R^b3, NR^c3C(O)OR^a3, NR^c3C(O)NR^c3R^d3, C(=NR^e3)R^b3, C(=NR^e3)NR^c3R^d3, NR^c3C(=NR^e3)NR^c3R^d3, NR^c3S(O)R^b3, NR^c3S(O)2R^b3, NR^c3S(O)2NR^c3R^d3, S(O)R^b3, S(O)NR^c3R^d3, S(O)2R^b3, and S(O)2NR^c3R^d3;

or R³ and R⁵ together with the carbon atoms to which they are attached form a C_5-10 cycloalkyl ring or a 5-10 membered heterocycloalkyl ring, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C1-6 haloalkyl, CN, NO2, OR^a3, SR^a3, C(O)R^b3, C(O)NR^c3R^d3, C(O)OR^a3, OC(O)R^b3, OC(O)NR^c3R^d3, NR^c3R^d3, NR^c3C(O)R^b3, NR^c3C(O)OR^a3, NR^c3C(O)NR^c3R^d3, C(=NR^e3)R^b3, C(=NR^e3)NR^c3R^d3, NR^c3C(=NR^e3)NR^c3R^d3, NR^c3S(O)R^b3, NR^c3S(O)2R^b3, NR^c3S(O)2NR^c3R^d3, S(O)R^b3, S(O)NR^c3R^d3, S(O)₂R^b3, and S(O)₂NR^c3R^d3;

or R⁷ and R⁹ together with the carbon atoms to which they are attached form a C5-10 cycloalkyl ring or a 5-10 membered heterocycloalkyl ring, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C_1-6 haloalkyl, CN, NO₂, OR^a3, SR^a3, C(O)R^b3, C(O)NR^c3R^d3, C(O)OR^a3, OC(O)R^b3, OC(O)NR^c3R^d3, NR^c3R^d3, NR^c3C(O)R^b3, NR^c3C(O)OR^a3, NR^c3C(O)NR^c3R^d3, C(=NR^e3)R^b3, C(=NR^e3)NR^c3R^d3, NR^c3C(=NR^e3)NR^c3R^d3, NR^c3S(O)R^b3, NR^c3S(O)₂R^b3, NR^c3S(O)₂NR^c3R^d3, S(O)R^b3, S(O)NR^c3R^d3, S(O)2R^b3, and S(O)2NR^c3R^d3;

or R⁹ and R¹¹ together with the carbon atoms to which they are attached form a C_5-10 cycloalkyl ring or a 5-10 membered heterocycloalkyl ring, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C_1-6 haloalkyl, CN, NO₂, OR^a3, SR^a3, C(O)R^b3, C(O)NR^c3R^d3, C(O)OR^a3, OC(O)R^b3, OC(O)NR^c3R^d3, NR^c3R^d3, NR^c3C(O)R^b3, NR^c3C(O)OR^a3, NR^c3C(O)NR^c3R^d3, C(=NR^e3)R^b3, C(=NR^e3)NR^c3R^d3, NR^c3C(=NR^e3)NR^c3R^d3, NR^c3S(O)R^b3, NR^c3S(O)₂R^b3, NR^c3S(O)₂NR^c3R^d3, S(O)R^b3, S(O)NR^c3R^d3, S(O)2R^b3, and S(O)2NR^c3R^d3;

or R⁵ and R⁷ together with the carbon atoms to which they are attached and together with Y² form a 5-10 membered heterocycloalkyl ring optionally substituted with 1, 2, or 3 substituents independently selected from halo, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, CN, NO2, OR^a3, SR^a3, C(O)R^b3, C(O)NR^c3R^d3, C(O)OR^a3, OC(O)R^b3,

OC(O)NR^c3R^d3, NR^c3R^d3, NR^c3C(O)R^b3, NR^c3C(O)OR^a3, NR^c3C(O)NR^c3R^d3, C(=NR^e3)R^b3, C(=NR^e3)NR^c3R^d3, NR^c3C(=NR^e3)NR^c3R^d3, NR^c3S(O)R^b3, NR^c3S(O)2R^b3, NR^c3S(O)2NR^c3R^d3, S(O)R^b3, S(O)NR^c3R^d3, S(O)₂R^b3, and S(O)₂NR^c3R^d3;

or R¹ and R³ together form a double bond between the carbon atoms to which they are attached;

or R³ and R⁵ together form a double bond between the carbon atoms to which they are attached;

or R⁷ and R⁹ together form a double bond between the carbon atoms to which they are attached;

or R⁹ and R¹¹ together form a double bond between the carbon atoms to which they are attached;

or R⁹, R¹⁰, R¹¹, and R¹² together form a triple bond between the carbon atoms to which they are attached;

each R^a, R^b, R^c, R^d, R^a1, R^b1, R^c1, R^d1, R^a2, R^b2, R^c2, R^d2, R^a3, R^b3, R^c3, and R^d3 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C_3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_6-10 aryl-C_1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C_1-4 alkyl, wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_6-10 aryl, C_3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C_3-7 cycloalkyl-C_1-4 alkyl, 5-10 membered heteroaryl-C_1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl of said R^a, R^b, R^c, R^d, R^a1, R^b1, R^c1, R^d1, R^a2, R^b2, R^c2, R^d2, R^a3, R^b3, R^c3, and R^d3 is optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, OR^a7, SR^a7, C(O)R^b7, C(O)NR^c7R^d7, C(O)OR^a7, OC(O)R^b7, OC(O)NR^c7R^d7, NR^c7R^d7, NR^c7C(O)R^b7,

NR^c7C(O)NR^c7R^d7, NR^c7C(O)OR^a7, C(=NR^e7)NR^c7R^d7, NR^c7C(=NR^e7)NR^c3R^d7, S(O)R^b7, S(O)NR^c7R^d7, S(O)2R^b7, NR^c7S(O)2R^b7, NR^c7S(O)2NR^c7R^d7, and S(O)2NR^c7R^d7; or R^c and R^d together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from CN, halo, C1-4 alkyl, C1-4 haloalkyl, C1-6 haloalkyl, C2-6 alkenyl, C_2-6 alkynyl, CN, OR^a7, SR^a7, C(O)R^b7, C(O)NR^c7R^d7, C(O)OR^a7, OC(O)R^b7, OC(O)NR^c7R^d7, NR^c7R^d7, NR^c7C(O)R^b7, NR^c7C(O)NR^c7R^d7, NR^c7C(O)OR^a7, C(=NR^e7)NR^c7R^d7,

NR^c7C(=NR^e7)NR^c3R^d7, S(O)R^b7, S(O)NR^c7R^d7, S(O)₂R^b7, NR^c7S(O)₂R^b7, NR^c7S(O)₂NR^c7R^d7, and S(O)2NR^c7R^d7;

or R^c1 and R^d2 together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from CN, halo, C_1-4 alkyl, C_1-4 haloalkyl, C_1-6 haloalkyl, C_2-6 alkenyl, C2-6 alkynyl, CN, OR^a7, SR^a7, C(O)R^b7, C(O)NR^c7R^d7, C(O)OR^a7, OC(O)R^b7, OC(O)NR^c7R^d7, NR^c7R^d7, NR^c7C(O)R^b7, NR^c7C(O)NR^c7R^d7, NR^c7C(O)OR^a7, C(=NR^e7)NR^c7R^d7,

NR^c7C(=NR^e7)NR^c3R^d7, S(O)R^b7, S(O)NR^c7R^d7, S(O)2R^b7, NR^c7S(O)2R^b7, NR^c7S(O)2NR^c7R^d7, and S(O)2NR^c7R^d7;

or R^c2 and R^d2 together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from CN, halo, C_1-4 alkyl, C_1-4 haloalkyl, C_1-6 haloalkyl, C_2-6 alkenyl, C2-6 alkynyl, CN, OR^a7, SR^a7, C(O)R^b7, C(O)NR^c7R^d7, C(O)OR^a7, OC(O)R^b7, OC(O)NR^c7R^d7, NR^c7R^d7, NR^c7C(O)R^b7, NR^c7C(O)NR^c7R^d7, NR^c7C(O)OR^a7, C(=NR^e7)NR^c7R^d7,

NR^c7C(=NR^e7)NR^c3R^d7, S(O)R^b7, S(O)NR^c7R^d7, S(O)2R^b7, NR^c7S(O)2R^b7, NR^c7S(O)2NR^c7R^d7, and S(O)₂NR^c7R^d7;

or R^c3 and R^d3 together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from CN, halo, C1-4 alkyl, C1-4 haloalkyl, C1-6 haloalkyl, C2-6 alkenyl, C_2-6 alkynyl, CN, OR^a7, SR^a7, C(O)R^b7, C(O)NR^c7R^d7, C(O)OR^a7, OC(O)R^b7, OC(O)NR^c7R^d7, NR^c7R^d7, NR^c7C(O)R^b7, NR^c7C(O)NR^c7R^d7, NR^c7C(O)OR^a7, C(=NR^e7)NR^c7R^d7,

NR^c7C(=NR^e7)NR^c3R^d7, S(O)R^b7, S(O)NR^c7R^d7, S(O)₂R^b7, NR^c7S(O)₂R^b7, NR^c7S(O)₂NR^c7R^d7, and S(O)2NR^c7R^d7;

R^a7, R^b7, R^c7, and R^d7 are independently selected from H, C_1-6 alkyl, C_1-6 haloalkyl, C_2- 6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_6-10 aryl-C_1-4 alkyl, C_3-7 cycloalkyl-C_1-4 alkyl, 5-10 membered heteroaryl- C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl, wherein said C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4- 10 membered heterocycloalkyl, C_6-10 aryl-C_1-4 alkyl, C_3-7 cycloalkyl-C_1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl are each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-6 alkyl, C1-6 alkoxy, C1-6 haloalkyl, and C1-6 haloalkoxy;

each R^e, R^e1, R^e2, R^e3, and R^e7 is independently selected from H, C_1-4 alkyl, and CN; a is 0 or 1;

m is 0 or 1;

n is 0 or 1;

p is 0 or 1;

q is 0 or 1;

r is 0 or 1;

wherein any aforementioned heteroaryl or heterocycloalkyl group comprises 1, 2, 3, or 4 ring-forming heteroatoms independently selected from O, N, and S; and

wherein one or more ring-forming C or N atoms of any aforementioned

heterocycloalkyl group is optionally substituted by an oxo (=O) group. 4. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof wherein A is group having the formula (A-1a):

-1a). 5. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof wherein A is group having the formula (A-1b):

-1b). 6. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof wherein A is group having the formula (A-1c):

-1c); wherein Z¹ and Z² are each independently selected from N and CH, and wherein R is CN, Cl, or CF₃. 7. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof wherein A is group having the formula (A-1d):

-1d);

wherein Z¹ and Z² are each independently selected from N and CH, and wherein R is CN, Cl, or CF₃. 8. The compound of any one of claims 1-3, or a pharmaceutically acceptable salt thereof wherein L is NR^Y or O. 9. The compound of any one of claims 1-8, or a pharmaceutically acceptable salt thereof, wherein X is CF3, CH3, CN, Cl or Br. 10. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein Y¹ is NR^Y or O. 11. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein Y¹ is NR^Y, O, or S. 12. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein Y¹ is NR^Y. 13. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein Y¹ is O. 14. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof, wherein Y² is NR^Y or O. 15. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof, wherein Y² is NR^Y, O, or S. 16. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof, wherein Y² is O.

17. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein Y³ is C(=O). 18. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein Y³ is C(=O) or S(=O)2. 19. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt thereof, wherein R^Y is H or C1-4 alkyl. 20. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt thereof, wherein R^Y is methyl. 21. The compound of any one of claims 1-18, or a pharmaceutically acceptable salt thereof, wherein R^Y is H. 22. The compound of any one of claims 1-21, or a pharmaceutically acceptable salt thereof, wherein Z is H, Cy^Z, halo, C1-6 alkyl, C1-6 haloalkyl, CN, NO2, OR^a, C(O)R^b, C(O)NR^cR^d, C(O)OR^a, NR^cR^d, and NR^cC(O)R^b; wherein said C1-6 alkyl and C1-6 haloalkyl of Z are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Cy^Z, halo, CN, NO2, OR^a, SR^a, C(O)R^b, C(O)NR^cR^d, C(O)OR^a, OC(O)R^b, OC(O)NR^cR^d, NR^cR^d, and NR^cC(O)R^b. 23. The compound of any one of claims 1-21, or a pharmaceutically acceptable salt thereof, wherein Z is Cy^Z. 24. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt thereof, wherein Cy^Z is selected from 5-10 membered heteroaryl and 4-10 membered heterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO2, OR^a1, SR^a1, C(O)R^b1, C(O)NR^c1R^d1, C(O)OR^a1, OC(O)R^b1, OC(O)NR^c1R^d1, C(=NR^e1)NR^c1R^d1,

S(O)2NR^c1R^d1, wherein the alkyl, C2-6 alkenyl, and C2-6 alkynyl are optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO₂, OR^a1, SR^a1, C(O)R^b1, C(O)NR^c1R^d1, C(O)OR^a1, OC(O)R^b1, OC(O)NR^c1R^d1, C(=NR^e1)NR^c1R^d1,

NR^c1C(=NR^e1)NR^c1R^d1, NR^c1R^d1, NR^c1C(O)R^b1, NR^c1C(O)OR^a1, NR^c1C(O)NR^c1R^d1, NR^c1S(O)R^b1, NR^c1S(O)2R^b1, NR^c1S(O)2NR^c1R^d1, S(O)R^b1, S(O)NR^c1R^d1, S(O)2R^b1, and S(O)₂NR^c1R^d1. 25. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt thereof, wherein Cy^Z is 5-10 membered heteroaryl, optionally substituted by CN, CF3, or Cl. 26. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt thereof, wherein Cy^Z is 5-10 membered heteroaryl, optionally substituted by CN, C1-6 alkyl, C_1-6 haloalkyl, halo, or NR^c1R^d1, wherein C_1-6alkyl is optionally substituted with CN or NR^c1R^d1. 27. The compound of any one of claims 1-23, or a pharmaceutically acceptable salt thereof, wherein Cy^Z is pyridinyl or pyrimidinyl, each optionally substituted by CN, CF3, or Cl. 28. The compound of any one of claims 1-27, or a pharmaceutically acceptable salt thereof, wherein Ring D is a monocyclic or polycyclic 4-10 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 groups independently selected from halo, C_1-6 alkyl, C1-6 haloalkyl, CN, NO2, OR^a2, C(O)R^b2, C(O)NR^c2R^d2, C(O)OR^a2, NR^c2R^d2,

NR^c2C(O)R^b2, wherein the C_1-6 alkyl is optionally substituted with 1, 2, or 3 groups independently selected from halo, CN, NO2, OR^a2, C(O)R^b2, NR^c2R^d2, and NR^c2C(O)R^b2. 29. The compound of any one of claims 1-27, or a pharmaceutically acceptable salt thereof, wherein Ring D is a monocyclic 4-10 membered heterocycloalkyl group. 30. The compound of any one of claims 1-27, or a pharmaceutically acceptable salt thereof, wherein Ring D is piperazinyl. 31. The compound of any one of claims 1-27, or a pharmaceutically acceptable salt thereof, wherein Ring D is piperazinyl, dihydropyridazinyl, diazepanyl, pyrrolidinyl, or hexahydropyrrolo[3,2-b]pyrrol-1(2H)-yl. 32. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein R¹ is H, halo, OR^a3, C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, C6-10 aryl-C1-4 alkyl, wherein said C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C1-4 alkyl is optionally substituted with OR^a3 or NR^c3R^d3.

33. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein R¹ is H, halo, OR^a3, C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, or 4- 10 membered heterocycloalkyl-C_1-4 alkyl, wherein said C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, C6-10 aryl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl or 4-10 membered heterocycloalkyl-C_1-4 alkyl is optionally substituted with OR^a3 or NR^c3R^d3. 34. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein R¹ is C_1-6 alkyl. 35. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein R¹ is C1-6 alkyl, optionally substituted with OR^a3. 36. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein R¹ is H. 37. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein R¹ is methyl, ethyl, or isopropyl. 38. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein R¹ is methoxymethyl or hydroxymethyl. 39. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein R¹ is phenyl, phenylmethyl, or pyridinyl. 40. The compound of any one of claims 1-39, or a pharmaceutically acceptable salt thereof, wherein R² is H, halo, OR^a3, C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, C6-10 aryl-C_1-4 alkyl, wherein said C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C_6-10 aryl-C_1-4 alkyl is optionally substituted with OR^a3 or NR^c3R^d3. 41. The compound of any one of claims 1-39, or a pharmaceutically acceptable salt thereof, wherein R² is OR^a3. 42. The compound of any one of claims 1-39, or a pharmaceutically acceptable salt thereof, wherein R² is H. 43. The compound of any one of claims 1-42 or a pharmaceutically acceptable salt thereof, wherein R³ is H, halo, OR^a3, C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, C6-10 aryl-C1-4 alkyl, wherein said C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C1-4 alkyl is optionally substituted with OR^a3 or NR^c3R^d3. 44. The compound of any one of claims 1-42, or a pharmaceutically acceptable salt thereof, wherein R³ is H. 45. The compound of any one of claims 1-42, or a pharmaceutically acceptable salt thereof, wherein R³ is methyl, ethyl, or isopropyl. 46. The compound of any one of claims 1-42, or a pharmaceutically acceptable salt thereof, wherein R³ is methoxymethyl or hydroxymethyl. 47. The compound of any one of claims 1-42, or a pharmaceutically acceptable salt thereof, wherein R³ is phenyl, phenylmethyl, or pyridinyl. 48. The compound of any one of claims 1-47, or a pharmaceutically acceptable salt thereof, wherein R⁴ is H, halo, OR^a3, C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, C6-10 aryl-C1-4 alkyl, wherein said C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C1-4 alkyl is optionally substituted with OR^a3 or NR^c3R^d3. 49. The compound of any one of claims 1-47, or a pharmaceutically acceptable salt thereof, wherein R⁴ is H. 50. The compound of any one of claims 1-48, or a pharmaceutically acceptable salt thereof, wherein R⁵ is H, halo, OR^a3, C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, C6-10 aryl-C_1-4 alkyl, wherein said C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C_6-10 aryl-C_1-4 alkyl is optionally substituted with OR^a3 or NR^c3R^d3. 51. The compound of any one of claims 1-49, or a pharmaceutically acceptable salt thereof, wherein R⁵ is H. 52. The compound of any one of claims 1-49, or a pharmaceutically acceptable salt thereof, wherein R⁵ is methyl, ethyl, or isopropyl. 53. The compound of any one of claims 1-49, or a pharmaceutically acceptable salt thereof, wherein R⁵ is methoxymethyl or hydroxymethyl.

54. The compound of any one of claims 1-49, or a pharmaceutically acceptable salt thereof, wherein R⁵ is phenyl, phenylmethyl, or pyridinyl. 55. The compound of any one of claims 1-54, or a pharmaceutically acceptable salt thereof, wherein R⁶ is H, halo, OR^a3, C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, C6-10 aryl-C_1-4 alkyl, wherein said C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C_6-10 aryl-C_1-4 alkyl is optionally substituted with OR^a3 or NR^c3R^d3. 56. The compound of any one of claims 1-54, or a pharmaceutically acceptable salt thereof, wherein R⁶ is H. 57. The compound of any one of claims 1-56, or a pharmaceutically acceptable salt thereof, wherein R⁷ is H, halo, OR^a3, C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, C6-10 aryl-C_1-4 alkyl, wherein said C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C_6-10 aryl-C_1-4 alkyl is optionally substituted with OR^a3 or NR^c3R^d3. 58. The compound of any one of claims 1-56, or a pharmaceutically acceptable salt thereof, wherein R⁷ is C_1-6 alkyl. 59. The compound of any one of claims 1-56, or a pharmaceutically acceptable salt thereof, wherein R⁷ is methyl. 60. The compound of any one of claims 1-59, or a pharmaceutically acceptable salt thereof, wherein R⁸ is H, halo, OR^a3, C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C_1-4 alkyl, wherein said C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C_6-10 aryl-C_1-4 alkyl is optionally substituted with OR^a3 or NR^c3R^d3. 61. The compound of any one of claims 1-59, or a pharmaceutically acceptable salt thereof, wherein R⁸ is H. 62. The compound of any one of claims 1-61, or a pharmaceutically acceptable salt thereof, wherein R⁹ is H, halo, OR^a3, C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C1-4 alkyl, wherein said C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C1-4 alkyl is optionally substituted with OR^a3 or NR^c3R^d3. 63. The compound of any one of claims 1-61, or a pharmaceutically acceptable salt thereof, wherein R⁹ is H.

64. The compound of any one of claims 1-61, or a pharmaceutically acceptable salt thereof, wherein R¹⁰ is H, halo, OR^a3, C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C_6- 10 aryl-C1-4 alkyl, wherein said C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl- C_1-4 alkyl is optionally substituted with OR^a3 or NR^c3R^d3. 65. The compound of any one of claims 1-61, or a pharmaceutically acceptable salt thereof, wherein R¹⁰ is H. 66. The compound of any one of claims 1-65, or a pharmaceutically acceptable salt thereof, wherein R¹¹ is H, halo, OR^a3, C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C6- ₁₀ aryl-C_1-4 alkyl, wherein said C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C_6-10 aryl- C1-4 alkyl is optionally substituted with OR^a3 or NR^c3R^d3. 67. The compound of any one of claims 1-65, or a pharmaceutically acceptable salt thereof, wherein R¹¹ is H. 68. The compound of any one of claims 1-67, or a pharmaceutically acceptable salt thereof, wherein R¹² is H, halo, OR^a3, C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C_6- 10 aryl-C1-4 alkyl, wherein said C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl- C_1-4 alkyl is optionally substituted with OR^a3 or NR^c3R^d3. 69. The compound of any one of claims 1-67, or a pharmaceutically acceptable salt thereof, wherein R¹² is H. 70. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein R¹, R², R³, R⁴, R⁵, R⁶, R⁷, and R⁸ are each H. 71. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein R⁷, R⁸, R⁹, R¹⁰, R¹¹, and R¹² are each H. 72. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein R¹, R², R⁵, R⁶, R⁷, R⁸, R⁹, and R¹⁰ are each H. 73. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein R², R⁵, R⁶, R⁷, R⁸, R⁹, and R¹⁰ are each H. 74. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein R⁵, R⁶, R⁷, R⁸, R⁹, and R¹⁰ are each H

75. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein R³ and R⁵ together with the carbon atoms to which they are attached form a C5-10 cycloalkyl ring or a 5-10 membered heterocycloalkyl ring, each optionally substituted with 1, 2, or 3 substituents independently selected from halo, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C1-6 haloalkyl, CN, NO2, OR^a3, SR^a3, C(O)R^b3, C(O)NR^c3R^d3, C(O)OR^a3, OC(O)R^b3, OC(O)NR^c3R^d3, NR^c3R^d3, NR^c3C(O)R^b3, NR^c3C(O)OR^a3, NR^c3C(O)NR^c3R^d3, C(=NR^e3)R^b3, C(=NR^e3)NR^c3R^d3, NR^c3C(=NR^e3)NR^c3R^d3, NR^c3S(O)R^b3, NR^c3S(O)2R^b3, NR^c3S(O)2NR^c3R^d3, S(O)R^b3, S(O)NR^c3R^d3, S(O)₂R^b3, and S(O)₂NR^c3R^d3. 76. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein R³ and R⁵ together with the carbon atoms to which they are attached form a C5-10 cycloalkyl ring or a 5-10 membered heterocycloalkyl ring. 77. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein R³ and R⁵ together with the carbon atoms to which they are attached form a tetrahydrofuranyl ring. 78. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein R³ and R⁵ together with the carbon atoms to which they are attached form a cyclobutyl or cyclopentyl ring. 79. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein R⁵ and R⁷ together with the carbon atoms to which they are attached and together with Y² form a 5-10 membered heterocycloalkyl ring optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO2, OR^a3, SR^a3, C(O)R^b3, C(O)NR^c3R^d3, C(O)OR^a3, OC(O)R^b3, OC(O)NR^c3R^d3, NR^c3R^d3, NR^c3C(O)R^b3, NR^c3C(O)OR^a3, NR^c3C(O)NR^c3R^d3, C(=NR^e3)R^b3, C(=NR^e3)NR^c3R^d3, NR^c3C(=NR^e3)NR^c3R^d3, NR^c3S(O)R^b3, NR^c3S(O)2R^b3, NR^c3S(O)2NR^c3R^d3, S(O)R^b3, S(O)NR^c3R^d3, S(O)₂R^b3, and S(O)₂NR^c3R^d3. 80. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein R⁵ and R⁷ together with the carbon atoms to which they are attached and together with Y² form a 5-10 membered heterocycloalkyl ring.

81. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein R⁵ and R⁷ together with the carbon atoms to which they are attached and together with Y² form a tetrahydrofuranyl ring or tetrahydropyranyl ring. 82. The compound of any one of claims 1-31, or a pharmaceutically acceptable salt thereof, wherein R⁵ and R⁷ together with the carbon atoms to which they are attached and together with Y² form a tetrahydrofuranyl ring, tetrahydropyranyl ring, or pyrrolidinyl ring. 83. The compound of any one of claims 1-82, or a pharmaceutically acceptable salt thereof, wherein R^a3 is C1-6 alkyl or H. 84. The compound of any one of claims 1-82, or a pharmaceutically acceptable salt thereof, wherein R^a3 is methyl. 85. The compound of any one of claims 1-82, or a pharmaceutically acceptable salt thereof, wherein R^a3 is H. 86. The compound of any one of claims 1-85, or a pharmaceutically acceptable salt thereof, wherein R^c3 and R^d3 are each independently selected from C_1-6 alkyl and H. 87. The compound of any one of claims 1-85, or a pharmaceutically acceptable salt thereof, wherein R^c3 is C1-6 alkyl or H. 88. The compound of any one of claims 1-85, or a pharmaceutically acceptable salt thereof, wherein R^d3 is C1-6 alkyl or H. 89. The compound of any one of claims 1-85, or a pharmaceutically acceptable salt thereof, wherein R^c3 and R^d3 are each methyl. 90. The compound of any one of claims 1-85, or a pharmaceutically acceptable salt thereof, wherein R^c3 and R^d3 are each H. 91. The compound of any one of claims 1-90, or a pharmaceutically acceptable salt thereof, wherein m is 1. 92. The compound of any one of claims 1-91, or a pharmaceutically acceptable salt thereof, wherein n is 0.

93. The compound of any one of claims 1-91, or a pharmaceutically acceptable salt thereof, wherein n is 1. 94. The compound of any one of claims 1-93, or a pharmaceutically acceptable salt thereof, wherein p is 0. 95. The compound of any one of claims 1-93, or a pharmaceutically acceptable salt thereof, wherein p is 1. 96. The compound of any one of claims 1-95, or a pharmaceutically acceptable salt thereof, wherein q is 0. 97. The compound of any one of claims 1-95, or a pharmaceutically acceptable salt thereof, wherein q is 1. 98. The compound of any one of claims 1-97, or a pharmaceutically acceptable salt thereof, wherein r is 0. 99. The compound of any one of claims 1-98, or a pharmaceutically acceptable salt thereof, wherein a is 0. 100. The compound of any one of claims 1-99, or a pharmaceutically acceptable salt thereof, having Formula IIa:

101. The compound of any one of claims 1-99, or a pharmaceutically acceptable salt thereof, having Formula IIb:

102. The compound of any one of claims 1-99, or a pharmaceutically acceptable salt thereof, having Formula IIc:

wherein Z¹ and Z² are each independently selected from N and CH, and wherein R is CN, Cl, or CF3. 103. The compound of any one of claims 1-99, or a pharmaceutically acceptable salt thereof, having Formula IId:

wherein Z¹ and Z² are each independently selected from N and CH, and wherein R is CN, Cl, or CF3. 104. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein A is the group having the formula A-2. 105. The compound of claim 1 or 104, or a pharmaceutically acceptable salt thereof, wherein: X is Cl, Br, CH3, CF3, CN, OCH3, cyclopropyl, SCH3, or isopropyl;

A is a group having the formula (A-2):

L is C_1-3 alkylene, O, S, NR^Y, C(=O), C(=O)O, C(=O)NR^Y, S(=O), S(=O)NR^Y, or NR^YC(=O)NR^Y;

Z is H, Cy^Z, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO2, OR^a, SR^a, C(O)R^b, C(O)NR^cR^d, C(O)OR^a, OC(O)R^b, OC(O)NR^cR^d, NR^cR^d, NR^cC(O)R^b,

NR^cC(O)OR^a, NR^cC(O)NR^cR^d, C(=NR^e)R^b, C(=NR^e)NR^cR^d, NR^cC(=NR^e)NR^cR^d,

NR^cS(O)R^b, NR^cS(O)₂R^b, NR^cS(O)₂NR^cR^d, S(O)R^b, S(O)NR^cR^d, S(O)₂R^b, and S(O)₂NR^cR^d; wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C1-6 haloalkyl of Z are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Cy^Z, halo, CN, NO₂, OR^a, SR^a, C(O)R^b, C(O)NR^cR^d, C(O)OR^a, OC(O)R^b, OC(O)NR^cR^d, C(=NR^e)NR^cR^d, NR^cC(=NR^e)NR^cR^d, NR^cR^d, NR^cC(O)R^b, NR^cC(O)OR^a, NR^cC(O)NR^cR^d, NR^cS(O)R^b, NR^cS(O)2R^b, NR^cS(O)2NR^cR^d, S(O)R^b, S(O)NR^cR^d, S(O)2R^b, and S(O)2NR^cR^d;

Cy^Z is selected from C_6-10 aryl, C_3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 substituents independently selected from halo, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, CN, NO2, OR^a1, SR^a1, C(O)R^b1, C(O)NR^c1R^d1, C(O)OR^a1, OC(O)R^b1, OC(O)NR^c1R^d1,

C(=NR^e1)NR^c1R^d1, NR^c1C(=NR^e1)NR^c1R^d1, NR^c1R^d1, NR^c1C(O)R^b1, NR^c1C(O)OR^a1, NR^c1C(O)NR^c1R^d1, NR^c1S(O)R^b1, NR^c1S(O)2R^b1, NR^c1S(O)2NR^c1R^d1, S(O)R^b1, S(O)NR^c1R^d1, S(O)₂R^b1, and S(O)₂NR^c1R^d1, wherein the alkyl, C_2-6 alkenyl, and C_2-6 alkynyl are optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO2, OR^a1, SR^a1, C(O)R^b1, C(O)NR^c1R^d1, C(O)OR^a1, OC(O)R^b1, OC(O)NR^c1R^d1, C(=NR^e1)NR^c1R^d1, NR^c1C(=NR^e1)NR^c1R^d1, NR^c1R^d1, NR^c1C(O)R^b1, NR^c1C(O)OR^a1, NR^c1C(O)NR^c1R^d1, NR^c1S(O)R^b1, NR^c1S(O)₂R^b1, NR^c1S(O)₂NR^c1R^d1, S(O)R^b1, S(O)NR^c1R^d1, S(O)₂R^b1, and S(O)2NR^c1R^d1;

R¹³, R¹⁴, and R¹⁵ are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4- 10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C_1-4 alkyl, 4-10 membered heterocycloalkyl-C_1-4 alkyl, CN, NO₂, OR^a4, SR^a4, C(O)R^b4, C(O)NR^c4R^d4, C(O)OR^a4, OC(O)R^b4, OC(O)NR^c4R^d4, NR^c4R^d4, NR^c4C(O)R^b4, NR^c4C(O)OR^a4, NR^c4C(O)NR^c4R^d4, C(=NR^e4)R^b4, C(=NR^e4)NR^c4R^d4, NR^c4C(=NR^e4)NR^c4R^d4, NR^c4S(O)R^b4, NR^c4S(O)₂R^b4, NR^c4S(O)₂NR^c4R^d4, S(O)R^b4, S(O)NR^c4R^d4, S(O)₂R^b4, and S(O)2NR^c4R^d4; wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C_3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_6-10 aryl-C_1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C_1-4 alkyl of said R¹³, R¹⁴, and R¹⁵ are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C_1-6 haloalkyl, CN, NO₂, OR^a4, SR^a4, C(O)R^b4, C(O)NR^c4R^d4, C(O)OR^a4, OC(O)R^b4, OC(O)NR^c4R^d4, NR^c4R^d4, NR^c4C(O)R^b4, NR^c4C(O)OR^a4, NR^c4C(O)NR^c4R^d4, C(=NR^e4)R^b4, C(=NR^e4)NR^c4R^d4, NR^c4C(=NR^e4)NR^c4R^d4, NR^c4S(O)R^b4, NR^c4S(O)₂R^b4, NR^c4S(O)₂NR^c4R^d4, S(O)R^b4, S(O)NR^c4R^d4, S(O)2R^b4, and S(O)2NR^c4R^d4;

Q¹, Q², and Q³ are each a group of formula (B-1):

Y⁴, Y⁵, and Y⁶ are each independently selected from O, S, NR^Y, C(=O), C(=O)O, C(=O)NR^Y, S(=O), S(=O)2, S(=O)NR^Y, S(=O)2NR^Y or NR^YC(=O)NR^Y;

G¹ is–C(R^G)(R^H)– or a group of formula (C-1), (C-2), or (C-3):

G² is–C(R^I)(R^J)– or a group of formula (C-1), (C-2), or (C-3); R^A, R^B, R^C, R^D, R^E, R^F, R^G, R^H, R^I, R^J, R^K, R^L, R^M, and R^N are each independently selected from H, halo, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_6-10 aryl, C_3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C_3-7 cycloalkyl-C_1-4 alkyl, 5-10 membered heteroaryl-C_1-4 alkyl, 4-10 membered

heterocycloalkyl-C1-4 alkyl, CN, NO2, OR^a5, SR^a5, C(O)R^b5, C(O)NR^c5R^d5, C(O)OR^a5, OC(O)R^b5, OC(O)NR^c5R^d5, C(=NR^e5)NR^c5R^d5, NR^c5C(=NR^e5)NR^c5R^d5, NR^c5R^d5,

NR^c5C(O)R^b5, NR^c5C(O)OR^a5, NR^c5C(O)NR^c5R^d5, NR^c5S(O)R^b5, NR^c5S(O)2R^b5,

NR^c5S(O)₂NR^c5R^d5, S(O)R^b5, S(O)NR^c5R^d5, S(O)₂R^b5, and S(O)₂NR^c5R^d5; wherein said C_1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_6-10 aryl-C_1-4 alkyl, C_3-7 cycloalkyl-C_1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl of said R^A, R^B, R^C, R^D, R^E, R^F, R^G, R^H, R^I, R^J, R^K, R^L, R^M, and R^N are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2- 6 alkynyl, C1-6 haloalkyl, CN, NO2, OR^a5, SR^a5, C(O)R^b5, C(O)NR^c5R^d5, C(O)OR^a5,

OC(O)R^b5, OC(O)NR^c5R^d5, C(=NR^e5)NR^c5R^d5, NR^c5C(=NR^e5)NR^c5R^d5, NR^c5R^d5,

NR^c5C(O)R^b5, NR^c5C(O)OR^a5, NR^c5C(O)NR^c5R^d5, NR^c5S(O)R^b5, NR^c5S(O)2R^b5,

NR^c5S(O)₂NR^c5R^d5, S(O)R^b5, S(O)NR^c5R^d5, S(O)₂R^b5, and S(O)₂NR^c5R^d5;

or R^G and R^I together with the carbon atoms to which they are attached and together with Y⁵ form a 5-10 membered heterocycloalkyl ring optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO₂, OR^a3, SR^a3, C(O)R^b3, C(O)NR^c3R^d3, C(O)OR^a3, OC(O)R^b3,

OC(O)NR^c3R^d3, NR^c3R^d3, NR^c3C(O)R^b3, NR^c3C(O)OR^a3, NR^c3C(O)NR^c3R^d3, C(=NR^e3)R^b3, C(=NR^e3)NR^c3R^d3, NR^c3C(=NR^e3)NR^c3R^d3, NR^c3S(O)R^b3, NR^c3S(O)₂R^b3, NR^c3S(O)₂NR^c3R^d3, S(O)R^b3, S(O)NR^c3R^d3, S(O)2R^b3, and S(O)2NR^c3R^d3;

or R^C and R^E together form a double bond between the carbon atoms to which they are attached;

or R^E and R^G together form a double bond between the carbon atoms to which they are attached;

or R^I and R^K together form a double bond between the carbon atoms to which they are attached;

or R^K and R^M together form a double bond between the carbon atoms to which they are attached;

or R^K, R^L, R^M, and R^N together form a triple bond between the carbon atoms to which they are attached; D¹ and D² are each independently selected from N and CH;

D³, D⁴, D⁵, D⁶, D⁷, D⁸, and D⁹ are each independently selected from N and CR^X, wherein each R^X is independently selected from H, halo, and C1-4 alkyl;

D¹⁰ is O, S, NH or CH₂;

Ring F is a mono- or polycyclic ring selected from C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C_1-6 haloalkyl, CN, NO₂, OR^a6, SR^a6, C(O)R^b6, C(O)NR^c6R^d6, C(O)OR^a6, OC(O)R^b6, OC(O)NR^c6R^d6, C(=NR^e6)NR^c6R^d6, NR^c6C(=NR^e6)NR^c6R^d6, NR^c6R^d6, NR^c6C(O)R^b6,

NR^c6C(O)OR^a6, NR^c6C(O)NR^c6R^d6, NR^c6S(O)R^b6, NR^c6S(O)₂R^b6, NR^c6S(O)₂NR^c6R^d6, S(O)R^b6, S(O)NR^c6R^d6, S(O)2R^b6, and S(O)2NR^c6R^d6, wherein the alkyl, C2-6 alkenyl, and C2-6 alkynyl are optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO2, OR^a6, SR^a6, C(O)R^b6, C(O)NR^c6R^d6, C(O)OR^a6, OC(O)R^b6, OC(O)NR^c6R^d6, C(=NR^e6)NR^c6R^d6, NR^c6C(=NR^e6)NR^c6R^d6, NR^c6R^d6, NR^c6C(O)R^b6, NR^c6C(O)OR^a6,

NR^c6C(O)NR^c6R^d6, NR^c6S(O)R^b6, NR^c6S(O)2R^b6, NR^c6S(O)2NR^c6R^d6, S(O)R^b6, S(O)NR^c6R^d6, S(O)2R^b6, and S(O)2NR^c6R^d6;

each R^a, R^b, R^c, R^d, R^a1, R^b1, R^c1, R^d1, R^a3, R^b3, R^c3, R^d3, R^a4, R^b4, R^c4, R^d4, R^a5, R^b5, R^c5, R^d5, R^a6, R^b6, R^c6, and R^d6 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2- ₆ alkenyl, C_2-6 alkynyl, C_6-10 aryl, C_3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C_1-4 alkyl, and 4-10 membered heterocycloalkyl-C_1-4 alkyl, wherein said C_1-6 alkyl, C_2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_6-10 aryl-C_1-4 alkyl, C_3-7 cycloalkyl-C_1-4 alkyl, 5-10 membered heteroaryl- C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl of said R^a, R^b, R^c, R^d, R^a1, R^b1, R^c1, R^d1, R^a2, R^b2, R^c2, R^d2, R^a3, R^b3, R^c3, R^d3, R^a4, R^b4, R^c4, R^d4, R^a5, R^b5, R^c5, R^d5, R^a6, R^b6, R^c6, and R^d6 is optionally substituted with 1, 2, or 3 substituents independently selected from halo, C_1-4 alkyl, C_1-4 haloalkyl, C_2-6 alkenyl, C_2-6 alkynyl, CN, OR^a7, SR^a7, C(O)R^b7, C(O)NR^c7R^d7, C(O)OR^a7, OC(O)R^b7, OC(O)NR^c7R^d7, NR^c7R^d7, NR^c7C(O)R^b7, NR^c7C(O)NR^c7R^d7,

NR^c7C(O)OR^a7, C(=NR^e7)NR^c7R^d7, NR^c7C(=NR^e7)NR^c3R^d7, S(O)R^b7, S(O)NR^c7R^d7, S(O)₂R^b7, NR^c7S(O)2R^b7, NR^c7S(O)2NR^c7R^d7, and S(O)2NR^c7R^d7;

or R^c and R^d together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from CN, halo, C1-4 alkyl, C1-4 haloalkyl, C1-6 haloalkyl, C2-6 alkenyl, C_2-6 alkynyl, CN, OR^a7, SR^a7, C(O)R^b7, C(O)NR^c7R^d7, C(O)OR^a7, OC(O)R^b7, OC(O)NR^c7R^d7, NR^c7R^d7, NR^c7C(O)R^b7, NR^c7C(O)NR^c7R^d7, NR^c7C(O)OR^a7, C(=NR^e7)NR^c7R^d7,

NR^c7C(=NR^e7)NR^c3R^d7, S(O)R^b7, S(O)NR^c7R^d7, S(O)₂R^b7, NR^c7S(O)₂R^b7, NR^c7S(O)₂NR^c7R^d7, and S(O)2NR^c7R^d7;

or R^c3 and R^d3 together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from CN, halo, C_1-4 alkyl, C_1-4 haloalkyl, C_1-6 haloalkyl, C_2-6 alkenyl, C2-6 alkynyl, CN, OR^a7, SR^a7, C(O)R^b7, C(O)NR^c7R^d7, C(O)OR^a7, OC(O)R^b7, OC(O)NR^c7R^d7, NR^c7R^d7, NR^c7C(O)R^b7, NR^c7C(O)NR^c7R^d7, NR^c7C(O)OR^a7, C(=NR^e7)NR^c7R^d7,

NR^c7C(=NR^e7)NR^c3R^d7, S(O)R^b7, S(O)NR^c7R^d7, S(O)2R^b7, NR^c7S(O)2R^b7, NR^c7S(O)2NR^c7R^d7, and S(O)₂NR^c7R^d7;

or R^c4 and R^d4 together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from CN, halo, C1-4 alkyl, C1-4 haloalkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, OR^a7, SR^a7, C(O)R^b7, C(O)NR^c7R^d7, C(O)OR^a7, OC(O)R^b7, OC(O)NR^c7R^d7, NR^c7R^d7, NR^c7C(O)R^b7, NR^c7C(O)NR^c7R^d7, NR^c7C(O)OR^a7, C(=NR^e7)NR^c7R^d7,

NR^c7C(=NR^e7)NR^c3R^d7, S(O)R^b7, S(O)NR^c7R^d7, S(O)2R^b7, NR^c7S(O)2R^b7, NR^c7S(O)2NR^c7R^d7, and S(O)₂NR^c7R^d7;

or R^c5 and R^d5 together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from CN, halo, C1-4 alkyl, C1-4 haloalkyl, C1-6 haloalkyl, C2-6 alkenyl, C_2-6 alkynyl, CN, OR^a7, SR^a7, C(O)R^b7, C(O)NR^c7R^d7, C(O)OR^a7, OC(O)R^b7, OC(O)NR^c7R^d7, NR^c7R^d7, NR^c7C(O)R^b7, NR^c7C(O)NR^c7R^d7, NR^c7C(O)OR^a7, C(=NR^e7)NR^c7R^d7,

NR^c7C(=NR^e7)NR^c3R^d7, S(O)R^b7, S(O)NR^c7R^d7, S(O)₂R^b7, NR^c7S(O)₂R^b7, NR^c7S(O)₂NR^c7R^d7, and S(O)2NR^c7R^d7;

or R^c6 and R^d6 together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from CN, halo, C_1-4 alkyl, C_1-4 haloalkyl, C_1-6 haloalkyl, C_2-6 alkenyl, C2-6 alkynyl, CN, OR^a7, SR^a7, C(O)R^b7, C(O)NR^c7R^d7, C(O)OR^a7, OC(O)R^b7, OC(O)NR^c7R^d7, NR^c7R^d7, NR^c7C(O)R^b7, NR^c7C(O)NR^c7R^d7, NR^c7C(O)OR^a7, C(=NR^e7)NR^c7R^d7,

NR^c7C(=NR^e7)NR^c3R^d7, S(O)R^b7, S(O)NR^c7R^d7, S(O)2R^b7, NR^c7S(O)2R^b7, NR^c7S(O)2NR^c7R^d7, and S(O)₂NR^c7R^d7;

R^a7, R^b7, R^c7, and R^d7 are independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2- 6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_6-10 aryl-C_1-4 alkyl, C_3-7 cycloalkyl-C_1-4 alkyl, 5-10 membered heteroaryl- C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl, wherein said C1-6 alkyl, C1-6 haloalkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_6-10 aryl, C_3-7 cycloalkyl, 5-10 membered heteroaryl, 4- 10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C_1-4 alkyl, and 4-10 membered heterocycloalkyl-C_1-4 alkyl are each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C_1-6 alkyl, C_1-6 alkoxy, C_1-6 haloalkyl, and C_1-6 haloalkoxy;

each R^e, R^e1, R^e3, R^e4, R^e5, R^e6 and R^e7 is independently selected from H, C1-4 alkyl, and CN;

a is 0 or 1;

b is 0, 1, 2, or 3;

c is 0, 1, or 2;

d is 0, 1, or 2;

m is 0 or 1;

n is 0 or 1;

p is 0 or 1;

q is 0 or 1;

r is 0 or 1;

s1 is 0, 1, or 2;

s2 is 0, 1, 2, or 3;

v is 0 or 1; and

w is 0 or 1;

wherein any aforementioned heteroaryl or heterocycloalkyl group comprises 1, 2, 3, or 4 ring-forming heteroatoms independently selected from O, N, and S; and

wherein one or more ring-forming C or N atoms of any aforementioned

heterocycloalkyl group is optionally substituted by an oxo (=O) group. 106. The compound of any one of claims 1, 104 and 105, or a pharmaceutically acceptable salt thereof, wherein Q¹ is a group of formula (B-1a):

-1a).

107. The compound of any one of claims 1, 104 and 105, or a pharmaceutically acceptable salt thereof, wherein Q¹ is a group of formula (B-1b):

108. The compound of any one of claims 1, 104 and 105, or a pharmaceutically acceptable salt thereof, wherein Q¹ is a group of formula (B-1c):

1c); wherein Z¹ and Z² are each independently selected from N and CH, and wherein R is CN, Cl, or CF3. 109. The compound of any one of claims 1 and 104-108, or a pharmaceutically acceptable salt thereof, wherein X is CF₃, CH₃, CN, Cl, or Br. 110. The compound of any one of claims 1 and 104-108, or a pharmaceutically acceptable salt thereof, wherein Ring F is 4-10 membered heterocycloalkyl or C_3-7 cycloalkyl optionally substituted with C1-6 alkyl, wherein said C1-6 alkyl is optionally substituted with OR^a6. 111. The compound of any one of claims 1 and 104-109, or a pharmaceutically acceptable salt thereof, wherein Ring F is 4-10 membered heterocycloalkyl or C3-7 cycloalkyl, each optionally substituted with methyl. 112. The compound of any one of claims 1 and 104-109, or a pharmaceutically acceptable salt thereof, wherein Ring F is piperazinyl, piperidinyl, pyrrolidinyl, 5,6,7,8-tetrahydro- [1,2,4]triazolo[4,3-a]pyrazinyl, 2,8-diazaspiro[4.5]decanyl, 2,5-diazabicyclo[2.2.2]octanyl, 1,4-diazepanyl, azetidinyl, 2,6-diazaspiro[3.3]heptanyl, 2,6-diazaspiro[3.4]octanyl, octahydropyrrolo[3,2-b]pyrrolyl, 2,7-diazaspiro[4.4]nonanyl, 2,5- diazabicyclo[2.2.1]heptanyl, octahydropyrrolo[3,4-c]pyrrolyl, or 2,7-diazaspiro[3.5]nonanyl.

113. The compound of any one of claims 1 and 104-109, or a pharmaceutically acceptable salt thereof, wherein Ring F is piperazinyl. 114. The compound of any one of claims 1 and 104-109, or a pharmaceutically acceptable salt thereof, wherein Ring F is cyclohexyl. 115. The compound of any one of claims 1 and 104-109, or a pharmaceutically acceptable salt thereof, wherein Ring F is 4-10 membered heterocycloalkyl, optionally substituted by an oxo (=O) group. 116. The compound of any one of claims 1 and 104-115, or a pharmaceutically acceptable salt thereof, wherein Z is Cy^Z, C1-6 alkyl, or C(O)R^b, wherein said C1-6 alkyl is optionally substituted by halo. 117. The compound of any one of claims 1 and 104-115, or a pharmaceutically acceptable salt thereof, wherein Z is CF₃. 118. The compound of any one of claims 1 and 104-116, or a pharmaceutically acceptable salt thereof, wherein Cy^Z is selected from 5-10 membered heteroaryl and C_6-10 aryl, optionally substituted by C1-6 alkyl, CN or CF3, wherein said C1-6 alkyl is optionally substituted with CN. 119. The compound of any one of claims 1 and 104-116, or a pharmaceutically acceptable salt thereof, wherein Cy^Z is pyridinyl, pyrimidinyl, or pyrazinyl, optionally substituted by C1- ₆ alkyl, CN, Cl, S(O)₂R^b1, or CF₃. 120. The compound of any one of claims 1 and 104-116, or a pharmaceutically acceptable salt thereof, wherein Cy^Z is pyridinyl, pyrimidinyl, or pyrazinyl, optionally substituted by methyl, CN, Cl, CF3, or S(O)2CH3. 121. The compound of any one of claims 1 and 104-116, or a pharmaceutically acceptable salt thereof, wherein Cy^Z is phenyl, optionally substituted with cyanomethyl or CN. 122. The compound of any one of claims 1 and 104-121, or a pharmaceutically acceptable salt thereof, wherein R^b is C_1-6 alkyl. 123. The compound of any one of claims 1 and 104-121, or a pharmaceutically acceptable salt thereof, wherein R^b is methyl.

124. The compound of any one of claims 1 and 104-123, or a pharmaceutically acceptable salt thereof, wherein Y⁴ is O or NR^Y. 125. The compound of any one of claims 1 and 104-123, or a pharmaceutically acceptable salt thereof, wherein Y⁴ is O. 126. The compound of any one of claims 1 and 104-123, or a pharmaceutically acceptable salt thereof, wherein Y⁴ is NR^Y. 127. The compound of any one of claims 1 and 104-126, or a pharmaceutically acceptable salt thereof, wherein Y⁵ is O, NR^Y, or C(=O)NR^Y. 128. The compound of any one of claims 1 and 104-127, or a pharmaceutically acceptable salt thereof, wherein Y⁶ is C(=O) or C(=O)NR^Y. 129. The compound of any one of claims 1 and 104-128, or a pharmaceutically acceptable salt thereof, wherein R^Y is H or C1-4 alkyl. 130. The compound of any one of claims 1 and 104-128, or a pharmaceutically acceptable salt thereof, wherein R^Y is H. 131. The compound of any one of claims 1 and 104-128, or a pharmaceutically acceptable salt thereof, wherein R^Y is methyl. 132. The compound of any one of claims 1 and 104-131, or a pharmaceutically acceptable salt thereof, wherein L is O or NR^Y. 133. The compound of any one of claims 1 and 104-132, or a pharmaceutically acceptable salt thereof, wherein G¹ is–C(R^G)(R^H)–. 134. The compound of any one of claims 1 and 104-133, or a pharmaceutically acceptable salt thereof, wherein G² is C-1. 135. The compound of any one of claims 1 and 104-134, or a pharmaceutically acceptable salt thereof, wherein D¹ and D² are each CH and D¹⁰ is CH2. 136. The compound of any one of claims 1 and 104-134, or a pharmaceutically acceptable salt thereof, wherein D¹ is CH, D² is N, and D¹⁰ is CH₂.

137. The compound of any one of claims 1 and 104-134, or a pharmaceutically acceptable salt thereof, wherein D³ is CH, D⁴ is N, D⁵ is CH. 138. The compound of any one of claims 1 and 104-137, or a pharmaceutically acceptable salt thereof, wherein D¹⁰ is CH2. 139. The compound of any one of claims 1 and 104-138, or a pharmaceutically acceptable salt thereof, wherein b is 0, c is 1, and d is 1. 140. The compound of any one of claims 1 and 104-0138, or a pharmaceutically acceptable salt thereof, wherein b is 0, c is 2, and d is 0. 141. The compound of any one of claims 1 and 104-138, or a pharmaceutically acceptable salt thereof, wherein b is 0, c is 0, and d is 0. 142. The compound of any one of claims 1 and 104-138, or a pharmaceutically acceptable salt thereof, wherein b is 0, c is 1, and d is 0. 143. The compound of any one of claims 1 and 104-142, or a pharmaceutically acceptable salt thereof, wherein G² is C-2. 144. The compound of any one of claims 1 and 104-143, or a pharmaceutically acceptable salt thereof, wherein D³, D⁴, and D⁵ are each CR^X, wherein each R^X is independently selected from H, halo, and C1-4 alkyl. 145. The compound of any one of claims 1 and 104-142, or a pharmaceutically acceptable salt thereof, wherein G² is C-3. 146. The compound of any one of claims 1 and 104-145, or a pharmaceutically acceptable salt thereof, wherein D⁶, D⁷, and D⁹ are CR^X, and D⁸ is N. 147. The compound of any one of claims 1 and 104-145, or a pharmaceutically acceptable salt thereof, wherein D⁶ and D⁷ are each N, and D⁸ and D⁹ are each CR^X. 148. The compound of any one of claims 1 and 104-145, or a pharmaceutically acceptable salt thereof, wherein D⁶, D⁷, D⁸, and D⁹ are each CR^X. 149. The compound of any one of claims 1 and 104-145, or a pharmaceutically acceptable salt thereof, wherein D⁶, D⁸, and D⁹ are each CR^X, and D⁷ is N.

150. The compound of any one of claims 1 and 104-145, or a pharmaceutically acceptable salt thereof, wherein D⁶, D⁷, and D⁸ are each CR^X and D⁹ is N. 151. The compound of any one of claims 1 and 104-145, or a pharmaceutically acceptable salt thereof, wherein D⁶ and D⁸ are each N, and D⁷ and D⁹ are each CR^X. 152. The compound of any one of claims 1 and 104-151, or a pharmaceutically acceptable salt thereof, wherein each R^X is H or halo. 153. The compound of any one of claims1 and 104-151, or a pharmaceutically acceptable salt thereof, wherein R^X is H or F. 154. The compound of any one of claims 1 and 104-151, or a pharmaceutically acceptable salt thereof, wherein R^X is H. 155. The compound of any one of claims 1 and 104-154, or a pharmaceutically acceptable salt thereof, wherein G² is–C(R^I)(R^J)– 156. The compound of any one of claims 1 and 104-155, or a pharmaceutically acceptable salt thereof, wherein R¹³ is C1-6 alkyl, OR^a4, CN, or NR^c4R^d4, wherein said C1-6 alkyl is optionally substituted with 1, 2, or 3 substituents independently selected from halo and OR^a4 and NR^c4R^d4. 157. The compound of any one of claims 1 and 104-155, or a pharmaceutically acceptable salt thereof, wherein R¹³ is methyl. 158. The compound of any one of claims 1 and 104-155, or a pharmaceutically acceptable salt thereof, wherein R¹³ is CN. 159. The compound of any one of claims 1 and 104-155, or a pharmaceutically acceptable salt thereof, wherein R¹³ is CF₃. 160. The compound of any one of claims 1 and 104-155, or a pharmaceutically acceptable salt thereof, wherein R¹³ is amino. 161. The compound of any one of claims 1 and 104-155, or a pharmaceutically acceptable salt thereof, wherein R¹³ is aminomethyl.

162. The compound of any one of claims 1 and 104-161, or a pharmaceutically acceptable salt thereof, wherein R^A is H, halo, OR^a5, C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C1-4 alkyl, wherein said C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C_1-4 alkyl is optionally substituted with OR^a5 or NR^c5R^d5. 163. The compound of any one of claims 1 and 104-161, or a pharmaceutically acceptable salt thereof, wherein R^A is C1-6 alkyl or H. 164. The compound of any one of claims 1 and 104-161, or a pharmaceutically acceptable salt thereof, wherein R^A is methyl. 165. The compound of any one of claims 1 and 104-161, or a pharmaceutically acceptable salt thereof, wherein R^A is H. 166. The compound of any one of claims 1 and 104-165, or a pharmaceutically acceptable salt thereof, wherein R^B is H, halo, OR^a5, C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C1-4 alkyl, wherein said C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C_1-4 alkyl is optionally substituted with OR^a5 or NR^c5R^d5. 167. The compound of any one of claims 1 and 104-165, or a pharmaceutically acceptable salt thereof, wherein R^B is C_1-6 alkyl or H. 168. The compound of any one of claims 1 and 104-165, or a pharmaceutically acceptable salt thereof, wherein R^B is methyl. 169. The compound of any one of claims 1 and 104-165, or a pharmaceutically acceptable salt thereof, wherein R^B is H. 170. The compound of any one of claims 1 and 104-169, or a pharmaceutically acceptable salt thereof, wherein R^C is H, halo, OR^a5, C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C1-4 alkyl, wherein said C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C1-4 alkyl is optionally substituted with OR^a5 or NR^c5R^d5. 171. The compound of any one of claims 1 and 104-169, or a pharmaceutically acceptable salt thereof, wherein R^C is C_1-6 alkyl or H. 172. The compound of any one of claims 1 and 104-169, or a pharmaceutically acceptable salt thereof, wherein R^C is methyl.

173. The compound of any one of claims 1 and 104-169, or a pharmaceutically acceptable salt thereof, wherein R^C is H. 174. The compound of any one of claims 1 and 104-173, or a pharmaceutically acceptable salt thereof, wherein R^D is H, halo, OR^a5, C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C_6-10 aryl-C_1-4 alkyl, wherein said C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C_6-10 aryl-C1-4 alkyl is optionally substituted with OR^a5 or NR^c5R^d5. 175. The compound of any one of claims 1 and 104-173, or a pharmaceutically acceptable salt thereof, wherein R^D is C1-6 alkyl or H. 176. The compound of any one of claims 1 and 104-173, or a pharmaceutically acceptable salt thereof, wherein R^D is methyl. 177. The compound of any one of claims 1 and 104-173, or a pharmaceutically acceptable salt thereof, wherein R^D is H. 178. The compound of any one of claims 1 and 104-177, or a pharmaceutically acceptable salt thereof, wherein R^E is H, halo, OR^a5, C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C1-4 alkyl, wherein said C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C_1-4 alkyl is optionally substituted with OR^a5 or NR^c5R^d5. 179. The compound of any one of claims 1 and 104-177, or a pharmaceutically acceptable salt thereof, wherein R^E is C1-6 alkyl or H. 180. The compound of any one of claims 1 and 104-177, or a pharmaceutically acceptable salt thereof, wherein R^E is methyl. 181. The compound of any one of claims 1 and 104-177, or a pharmaceutically acceptable salt thereof, wherein R^E is H. 182. The compound of any one of claims 1 and 104-181, or a pharmaceutically acceptable salt thereof, wherein R^F is H, halo, OR^a5, C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C1-4 alkyl, wherein said C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C_1-4 alkyl is optionally substituted with OR^a5 or NR^c5R^d5. 183. The compound of any one of claims 1 and 104-181, or a pharmaceutically acceptable salt thereof, wherein R^F is C1-6 alkyl or H.

184. The compound of any one of claims 1 and 104-181, or a pharmaceutically acceptable salt thereof, wherein R^F is methyl. 185. The compound of any one of claims 1 and 104-181, or a pharmaceutically acceptable salt thereof, wherein R^F is H. 186. The compound of any one of claims 1 and 104-185, or a pharmaceutically acceptable salt thereof, wherein R^G is H, halo, OR^a5, C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C_6-10 aryl-C_1-4 alkyl, wherein said C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C_6-10 aryl-C1-4 alkyl is optionally substituted with OR^a5 or NR^c5R^d5. 187. The compound of any one of claims 1 and 104-185, or a pharmaceutically acceptable salt thereof, wherein R^G is C1-6 alkyl or H. 188. The compound of any one of claims 1 and 104-185, or a pharmaceutically acceptable salt thereof, wherein R^G is methyl. 189. The compound of any one of claims 1 and 104-185, or a pharmaceutically acceptable salt thereof, wherein R^G is H. 190. The compound of any one of claims 1 and 104-189, or a pharmaceutically acceptable salt thereof, wherein R^H is H, halo, OR^a5, C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C_6-10 aryl-C_1-4 alkyl, wherein said C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C_6-10 aryl-C1-4 alkyl is optionally substituted with OR^a5 or NR^c5R^d5. 191. The compound of any one of claims 1 and 104-189, or a pharmaceutically acceptable salt thereof, wherein R^H is C1-6 alkyl or H. 192. The compound of any one of claims 1 and 104-189, or a pharmaceutically acceptable salt thereof, wherein R^H is methyl. 193. The compound of any one of claims 1 and 104-189, or a pharmaceutically acceptable salt thereof, wherein R^H is H. 194. The compound of any one of claims 1 and 104-193, or a pharmaceutically acceptable salt thereof, wherein R^I is H, halo, OR^a5, C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C_6-10 aryl-C_1-4 alkyl, wherein said C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C_6-10 aryl-C1-4 alkyl is optionally substituted with OR^a5 or NR^c5R^d5.

195. The compound of any one of claims 1 and 104-193, or a pharmaceutically acceptable salt thereof, wherein R^I is C_1-6 alkyl or H. 196. The compound of any one of claims 1 and 104-193, or a pharmaceutically acceptable salt thereof, wherein R^I is methyl. 197. The compound of any one of claims 1 and 104-193, or a pharmaceutically acceptable salt thereof, wherein R^I is H. 198. The compound of any one of claims 1 and 104-197, or a pharmaceutically acceptable salt thereof, wherein R^J is H, halo, OR^a5, C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C1-4 alkyl, wherein said C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C1-4 alkyl is optionally substituted with OR^a5 or NR^c5R^d5. 199. The compound of any one of claims 1 and 104-197, or a pharmaceutically acceptable salt thereof, wherein R^J is C_1-6 alkyl or H. 200. The compound of any one of claims 1 and 104-197, or a pharmaceutically acceptable salt thereof, wherein R^J is methyl. 201. The compound of any one of claims 1 and 104-197, or a pharmaceutically acceptable salt thereof, wherein R^J is H. 202. The compound of any one of claims 1 and 104-201, or a pharmaceutically acceptable salt thereof, wherein R^K is H, halo, OR^a5, C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C_6-10 aryl-C_1-4 alkyl, wherein said C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C_6-10 aryl-C1-4 alkyl is optionally substituted with OR^a5 or NR^c5R^d5. 203. The compound of any one of claims 1 and 104-201, or a pharmaceutically acceptable salt thereof, wherein R^K is C_1-6 alkyl or H. 204. The compound of any one of claims 1 and 104-201, or a pharmaceutically acceptable salt thereof, wherein R^K is methyl. 205. The compound of any one of claims 1 and 104-201, or a pharmaceutically acceptable salt thereof, wherein R^K is H.

206. The compound of any one of claims 1 and 104-205, or a pharmaceutically acceptable salt thereof, wherein R^L is H, halo, OR^a5, C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C1-4 alkyl, wherein said C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C_1-4 alkyl is optionally substituted with OR^a5 or NR^c5R^d5. 207. The compound of any one of claims 1 and 104-205, or a pharmaceutically acceptable salt thereof, wherein R^L is C1-6 alkyl or H. 208. The compound of any one of claims 1 and 104-205, or a pharmaceutically acceptable salt thereof, wherein R^L is methyl. 209. The compound of any one of claims 1 and 104-205, or a pharmaceutically acceptable salt thereof, wherein R^L is H. 210. The compound of any one of claims 104-209, or a pharmaceutically acceptable salt thereof, wherein R^M is H, halo, OR^a5, C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C_6- 10 aryl-C1-4 alkyl, wherein said C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl- C_1-4 alkyl is optionally substituted with OR^a5 or NR^c5R^d5. 211. The compound of any one of claims 1 and 104-209, or a pharmaceutically acceptable salt thereof, wherein R^M is C_1-6 alkyl or H. 212. The compound of any one of claims 1 and 104-209, or a pharmaceutically acceptable salt thereof, wherein R^M is methyl. 213. The compound of any one of claims 1 and 104-209, or a pharmaceutically acceptable salt thereof, wherein R^M is H. 214. The compound of any one of claims 1 and 104-213, or a pharmaceutically acceptable salt thereof, wherein R^N is H, halo, OR^a5, C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C1-4 alkyl, wherein said C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C1-4 alkyl is optionally substituted with OR^a5 or NR^c5R^d5. 215. The compound of any one of claims 1 and 104-213, or a pharmaceutically acceptable salt thereof, wherein R^N is C_1-6 alkyl or H. 216. The compound of any one of claims 1 and 104-213, or a pharmaceutically acceptable salt thereof, wherein R^N is methyl.

217. The compound of any one of claims 1 and 104-213, or a pharmaceutically acceptable salt thereof, wherein R^N is H. 218. The compound of any one of claims 1 and 104-217, or a pharmaceutically acceptable salt thereof, wherein R^I and R^K together form a double bond between the carbon atoms to which they are attached. 219. The compound of any one of claims 1 and 104-217, or a pharmaceutically acceptable salt thereof, wherein R^K and R^M together form a double bond between the carbon atoms to which they are attached. 220. The compound of any one of claims 1 and 104-217, or a pharmaceutically acceptable salt thereof, wherein R^K, R^L, R^M, and R^N together form a triple bond between the carbon atoms to which they are attached. 221. The compound of any one of claims 1 and 104-217, or a pharmaceutically acceptable salt thereof, wherein R^G and R^I together with the carbon atoms to which they are attached and together with Y⁵ form a 5-10 membered heterocycloalkyl ring optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C_1-6 haloalkyl, CN, NO₂, OR^a3, SR^a3, C(O)R^b3, C(O)NR^c3R^d3, C(O)OR^a3, OC(O)R^b3, OC(O)NR^c3R^d3, NR^c3R^d3, NR^c3C(O)R^b3, NR^c3C(O)OR^a3, NR^c3C(O)NR^c3R^d3, C(=NR^e3)R^b3, C(=NR^e3)NR^c3R^d3, NR^c3C(=NR^e3)NR^c3R^d3, NR^c3S(O)R^b3, NR^c3S(O)₂R^b3, NR^c3S(O)₂NR^c3R^d3, S(O)R^b3, S(O)NR^c3R^d3, S(O)2R^b3, and S(O)2NR^c3R^d3. 222. The compound of any one of claims 1 and 104-217, or a pharmaceutically acceptable salt thereof, wherein R^G and R^I together with the carbon atoms to which they are attached and together with Y⁵ form a tetrahydrofuranyl ring. 223. The compound of any one of claims 1 and 104-222, or a pharmaceutically acceptable salt thereof, wherein R^a6 is H. 224. The compound of any one of claims 1 and 104-223, or a pharmaceutically acceptable salt thereof, wherein R^b1 is C1-6 alkyl. 225. The compound of any one of claims 1 and 104-223, or a pharmaceutically acceptable salt thereof, wherein R^b1 is methyl.

226. The compound of any one of claims 1 and 104-225, or a pharmaceutically acceptable salt thereof, wherein R^a4 is H or C_1-6 alkyl. 227. The compound of any one of claims 1 and 104-225, or a pharmaceutically acceptable salt thereof, wherein R^a4 is methyl. 228. The compound of any one of claims 1 and 104-227, or a pharmaceutically acceptable salt thereof, wherein R^c4 and R^d4 are each H. 229. The compound of any one of claims 1 and 104-228, or a pharmaceutically acceptable salt thereof, wherein R^c5 and R^d5 are each H. 230. The compound of any one of claims 1 and 104-229, or a pharmaceutically acceptable salt thereof, wherein R^Y is H. 231. The compound of any one of claims 1 and 104-230, or a pharmaceutically acceptable salt thereof, wherein a is 0. 232. The compound of any one of claims 1 and 104-230, or a pharmaceutically acceptable salt thereof, wherein a is 1. 233. The compound of any one of claims 1 and 104-232, or a pharmaceutically acceptable salt thereof, wherein s1 is 0. 234. The compound of any one of claims 1 and 104-232, or a pharmaceutically acceptable salt thereof, wherein s1 is 1. 235. The compound of any one of claims 1 and 104-232, or a pharmaceutically acceptable salt thereof, wherein s1 is 2. 236. The compound of any one of claims 1 and 104-235, or a pharmaceutically acceptable salt thereof, wherein s2 is 0. 237. The compound of any one of claims 1 and 104-235, or a pharmaceutically acceptable salt thereof, wherein s2 is 1. 238. The compound of any one of claims 1 and 104-235, or a pharmaceutically acceptable salt thereof, wherein s2 is 2.

239. The compound of any one of claims 1 and 104-238, or a pharmaceutically acceptable salt thereof, wherein v is 0. 240. The compound of any one of claims 1 and 104-238, or a pharmaceutically acceptable salt thereof, wherein v is 1. 241. The compound of any one of claims 1 and 104-240, or a pharmaceutically acceptable salt thereof, wherein w is 0. 242. The compound of any one of claims 1 and 104-240, or a pharmaceutically acceptable salt thereof, wherein w is 1. 243. The compound of any one of claims 1 and 104-242, or a pharmaceutically acceptable salt thereof, wherein m is 0. 244. The compound of any one of claims 1 and 104-242, or a pharmaceutically acceptable salt thereof, wherein m is 1. 245. The compound of any one of claims 1 and 104-244, or a pharmaceutically acceptable salt thereof, wherein n is 0. 246. The compound of any one of claims 1 and 104-244, or a pharmaceutically acceptable salt thereof, wherein n is 1. 247. The compound of any one of claims 1 and 104-246, or a pharmaceutically acceptable salt thereof, wherein p is 0. 248. The compound of any one of claims 1 and 104-246, or a pharmaceutically acceptable salt thereof, wherein p is 1. 249. The compound of any one of claims 1 and 104-248, or a pharmaceutically acceptable salt thereof, wherein q is 0. 250. The compound of any one of claims 1 and 104-248, or a pharmaceutically acceptable salt thereof, wherein q is 1. 251. The compound of any one of claims 1 and 104-250, or a pharmaceutically acceptable salt thereof, wherein r is 0.

252. The compound of any one of claims 1 and 104-250, or a pharmaceutically acceptable salt thereof, wherein r is 1. 253. The compound of any one of claims 1 and 104-252, or a pharmaceutically acceptable salt thereof, having Formula IIIa:

IIIa. 254. The compound of any one of claims 1 and 104-252, or a pharmaceutically acceptable salt thereof, having Formula IIIb:

255. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein A is the group having the formula A-3. 256. The compound of claim 1 or 255, or a pharmaceutically acceptable salt thereof, wherein:

X is Cl, Br, CH₃, CF₃, CN, OCH₃, ethyl, cyclopropyl, SCH₃, or isopropyl;

A is a group having the formula (A-3): Y¹, Y², and Y³ are each independently selected from O, S, NR^Y, C(=O), C(=O)O, C(=O)NR^Y, S(=O), S(=O)₂, S(=O)NR^Y, S(=O)₂NR^Y or NR^YC(=O)NR^Y, wherein each R^Y is independently H or C1-4 alkyl;

L is C_1-3 alkylene, O, S, NR^Y, C(=O), C(=O)O, C(=O)NR^Y, S(=O), S(=O)NR^Y, or NR^YC(=O)NR^Y;

Z is H, Cy^Z, halo, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, CN, NO₂, OR^a, SR^a, C(O)R^b, C(O)NR^cR^d, C(O)OR^a, OC(O)R^b, OC(O)NR^cR^d, NR^cR^d, NR^cC(O)R^b, NR^cC(O)OR^a, NR^cC(O)NR^cR^d, C(=NR^e)R^b, C(=NR^e)NR^cR^d, NR^cC(=NR^e)NR^cR^d,

NR^cS(O)R^b, NR^cS(O)2R^b, NR^cS(O)2NR^cR^d, S(O)R^b, S(O)NR^cR^d, S(O)2R^b, and S(O)2NR^cR^d; wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, and C1-6 haloalkyl of Z are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from Cy^Z, halo, CN, NO2,

Cy^Z is selected from C_6-10 aryl, C_3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 substituents independently selected from halo, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, CN,

S(O)₂R^b1, and S(O)₂NR^c1R^d1, wherein the alkyl, C_2-6 alkenyl, and C_2-6 alkynyl are optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO2, OR^a1, SR^a1, C(O)R^b1, C(O)NR^c1R^d1, C(O)OR^a1, OC(O)R^b1, OC(O)NR^c1R^d1, C(=NR^e1)NR^c1R^d1,

R¹³, R¹⁴, and R¹⁵ are each independently selected from H, halo, C_1-6 alkyl, C_2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4- 10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C_1-4 alkyl, 4-10 membered heterocycloalkyl-C_1-4 alkyl, CN, NO₂, OR^a4, SR^a4, C(O)R^b4, C(O)NR^c4R^d4, C(O)OR^a4, OC(O)R^b4, OC(O)NR^c4R^d4, NR^c4R^d4, NR^c4C(O)R^b4, NR^c4C(O)OR^a4, NR^c4C(O)NR^c4R^d4, C(=NR^e4)R^b4, C(=NR^e4)NR^c4R^d4, NR^c4C(=NR^e4)NR^c4R^d4, NR^c4S(O)R^b4, NR^c4S(O)2R^b4, NR^c4S(O)2NR^c4R^d4, S(O)R^b4, S(O)NR^c4R^d4, S(O)2R^b4, and S(O)₂NR^c4R^d4; wherein said C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C_3-7 cycloalkyl-C_1-4 alkyl, 5-10 membered heteroaryl-C_1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl of said R¹³, R¹⁴, and R¹⁵ are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C1-6 haloalkyl, CN, NO2, OR^a4, SR^a4, C(O)R^b4, C(O)NR^c4R^d4, C(O)OR^a4, OC(O)R^b4, OC(O)NR^c4R^d4, NR^c4R^d4, NR^c4C(O)R^b4, NR^c4C(O)OR^a4, NR^c4C(O)NR^c4R^d4, C(=NR^e4)R^b4, C(=NR^e4)NR^c4R^d4, NR^c4C(=NR^e4)NR^c4R^d4, NR^c4S(O)R^b4, NR^c4S(O)2R^b4, NR^c4S(O)2NR^c4R^d4, S(O)R^b4, S(O)NR^c4R^d4, S(O)2R^b4, and S(O)2NR^c4R^d4;

Ring E is a mono- or polycyclic ring selected from C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl;

Q² and Q³ are each a group of formula (B-1):

Y⁴, Y⁵, and Y⁶ are each independently selected from O, S, NR^Y, C(=O), C(=O)O, C(=O)NR^Y, S(=O), S(=O)₂, S(=O)NR^Y, S(=O)₂NR^Y or NR^YC(=O)NR^Y;

G¹ is–C(R^G)(R^H)– or a group of formula (C-1), (C-2), or (C-3):

G² is–C(R^I)(R^J)– or a group of formula (C-1), (C-2), or (C-3);

R^A, R^B, R^C, R^D, R^E, R^F, R^G, R^H, R^I, R^J, R^K, R^L, R^M, and R^N are each independently selected from H, halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_6-10 aryl-C_1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered

heterocycloalkyl-C_1-4 alkyl, CN, NO₂, OR^a5, SR^a5, C(O)R^b5, C(O)NR^c5R^d5, C(O)OR^a5, OC(O)R^b5, OC(O)NR^c5R^d5, C(=NR^e5)NR^c5R^d5, NR^c5C(=NR^e5)NR^c5R^d5, NR^c5R^d5,

NR^c5C(O)R^b5, NR^c5C(O)OR^a5, NR^c5C(O)NR^c5R^d5, NR^c5S(O)R^b5, NR^c5S(O)₂R^b5,

NR^c5S(O)2NR^c5R^d5, S(O)R^b5, S(O)NR^c5R^d5, S(O)2R^b5, and S(O)2NR^c5R^d5; wherein said C1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, C_6-10 aryl, C_3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C_1-4 alkyl, and 4-10 membered heterocycloalkyl-C_1-4 alkyl of said R^A, R^B, R^C, R^D, R^E, R^F, R^G, R^H, R^I, R^J, R^K, R^L, R^M, and R^N are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C_1-6 alkyl, C_2-6 alkenyl, C_2- 6 alkynyl, C1-6 haloalkyl, CN, NO2, OR^a5, SR^a5, C(O)R^b5, C(O)NR^c5R^d5, C(O)OR^a5,

OC(O)R^b5, OC(O)NR^c5R^d5, C(=NR^e5)NR^c5R^d5, NR^c5C(=NR^e5)NR^c5R^d5, NR^c5R^d5,

NR^c5C(O)R^b5, NR^c5C(O)OR^a5, NR^c5C(O)NR^c5R^d5, NR^c5S(O)R^b5, NR^c5S(O)2R^b5,

NR^c5S(O)2NR^c5R^d5, S(O)R^b5, S(O)NR^c5R^d5, S(O)2R^b5, and S(O)2NR^c5R^d5;

or R^G and R^I together with the carbon atoms to which they are attached and together with Y⁵ form a 5-10 membered heterocycloalkyl ring optionally substituted with 1, 2, or 3 substituents independently selected from halo, C_1-6 alkyl, C_2-6 alkenyl, C_2-6 alkynyl, C_1-6 haloalkyl, CN, NO2, OR^a3, SR^a3, C(O)R^b3, C(O)NR^c3R^d3, C(O)OR^a3, OC(O)R^b3,

OC(O)NR^c3R^d3, NR^c3R^d3, NR^c3C(O)R^b3, NR^c3C(O)OR^a3, NR^c3C(O)NR^c3R^d3, C(=NR^e3)R^b3, C(=NR^e3)NR^c3R^d3, NR^c3C(=NR^e3)NR^c3R^d3, NR^c3S(O)R^b3, NR^c3S(O)2R^b3, NR^c3S(O)2NR^c3R^d3, S(O)R^b3, S(O)NR^c3R^d3, S(O)₂R^b3, and S(O)₂NR^c3R^d3;

or R^C and R^E together form a double bond between the carbon atoms to which they are attached;

or R^E and R^G together form a double bond between the carbon atoms to which they are attached; or R^I and R^K together form a double bond between the carbon atoms to which they are attached;

or R^K and R^M together form a double bond between the carbon atoms to which they are attached;

or R^K, R^L, R^M, and R^N together form a triple bond between the carbon atoms to which they are attached;

D¹ and D² are each independently selected from N and CH;

D³, D⁴, D⁵, D⁶, D⁷, D⁸, and D⁹ are each independently selected from N and CR^X, wherein each R^X is independently selected from H, halo, and C1-4 alkyl;

D¹⁰ is O, S, NH or CH₂;

Ring F is a mono- or polycyclic ring selected from C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, CN, NO2, OR^a6, SR^a6, C(O)R^b6, C(O)NR^c6R^d6, C(O)OR^a6, OC(O)R^b6, OC(O)NR^c6R^d6, C(=NR^e6)NR^c6R^d6, NR^c6C(=NR^e6)NR^c6R^d6, NR^c6R^d6, NR^c6C(O)R^b6,

NR^c6C(O)OR^a6, NR^c6C(O)NR^c6R^d6, NR^c6S(O)R^b6, NR^c6S(O)2R^b6, NR^c6S(O)2NR^c6R^d6, S(O)R^b6, S(O)NR^c6R^d6, S(O)₂R^b6, and S(O)₂NR^c6R^d6, wherein the alkyl, C_2-6 alkenyl, and C_2-6 alkynyl are optionally substituted with 1, 2, or 3 substituents independently selected from halo, CN, NO₂, OR^a6, SR^a6, C(O)R^b6, C(O)NR^c6R^d6, C(O)OR^a6, OC(O)R^b6, OC(O)NR^c6R^d6, C(=NR^e6)NR^c6R^d6, NR^c6C(=NR^e6)NR^c6R^d6, NR^c6R^d6, NR^c6C(O)R^b6, NR^c6C(O)OR^a6,

NR^c6C(O)NR^c6R^d6, NR^c6S(O)R^b6, NR^c6S(O)₂R^b6, NR^c6S(O)₂NR^c6R^d6, S(O)R^b6, S(O)NR^c6R^d6, S(O)2R^b6, and S(O)2NR^c6R^d6;

each R^a, R^b, R^c, R^d, R^a1, R^b1, R^c1, R^d1, R^a3, R^b3, R^c3, R^d3, R^a4, R^b4, R^c4, R^d4, R^a5, R^b5, R^c5, R^d5, R^a6, R^b6, R^c6, and R^d6 is independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2- ₆ alkenyl, C_2-6 alkynyl, C_6-10 aryl, C_3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C_1-4 alkyl, and 4-10 membered heterocycloalkyl-C_1-4 alkyl, wherein said C_1-6 alkyl, C_2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C_6-10 aryl-C_1-4 alkyl, C_3-7 cycloalkyl-C_1-4 alkyl, 5-10 membered heteroaryl- C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl of said R^a, R^b, R^c, R^d, R^a1, R^b1, R^c1, R^d1, R^a2, R^b2, R^c2, R^d2, R^a3, R^b3, R^c3, R^d3, R^a4, R^b4, R^c4, R^d4, R^a5, R^b5, R^c5, R^d5, R^a6, R^b6, R^c6, and R^d6 is optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-4 alkyl, C1-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, CN, OR^a7, SR^a7, C(O)R^b7, C(O)NR^c7R^d7, C(O)OR^a7, OC(O)R^b7, OC(O)NR^c7R^d7, NR^c7R^d7, NR^c7C(O)R^b7, NR^c7C(O)NR^c7R^d7, NR^c7C(O)OR^a7, C(=NR^e7)NR^c7R^d7, NR^c7C(=NR^e7)NR^c3R^d7, S(O)R^b7, S(O)NR^c7R^d7, S(O)2R^b7, NR^c7S(O)₂R^b7, NR^c7S(O)₂NR^c7R^d7, and S(O)₂NR^c7R^d7;

or R^c and R^d together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from CN, halo, C1-4 alkyl, C1-4 haloalkyl, C1-6 haloalkyl, C2-6 alkenyl, C_2-6 alkynyl, CN, OR^a7, SR^a7, C(O)R^b7, C(O)NR^c7R^d7, C(O)OR^a7, OC(O)R^b7, OC(O)NR^c7R^d7, NR^c7R^d7, NR^c7C(O)R^b7, NR^c7C(O)NR^c7R^d7, NR^c7C(O)OR^a7, C(=NR^e7)NR^c7R^d7,

NR^c7C(=NR^e7)NR^c3R^d7, S(O)R^b7, S(O)NR^c7R^d7, S(O)₂R^b7, NR^c7S(O)₂R^b7, NR^c7S(O)₂NR^c7R^d7, and S(O)2NR^c7R^d7;

or R^c1 and R^d1 together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from CN, halo, C_1-4 alkyl, C_1-4 haloalkyl, C_1-6 haloalkyl, C_2-6 alkenyl, C2-6 alkynyl, CN, OR^a7, SR^a7, C(O)R^b7, C(O)NR^c7R^d7, C(O)OR^a7, OC(O)R^b7, OC(O)NR^c7R^d7, NR^c7R^d7, NR^c7C(O)R^b7, NR^c7C(O)NR^c7R^d7, NR^c7C(O)OR^a7, C(=NR^e7)NR^c7R^d7,

NR^c7C(=NR^e7)NR^c3R^d7, S(O)R^b7, S(O)NR^c7R^d7, S(O)2R^b7, NR^c7S(O)2R^b7, NR^c7S(O)2NR^c7R^d7, and S(O)2NR^c7R^d7;

or R^c3 and R^d3 together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from CN, halo, C_1-4 alkyl, C_1-4 haloalkyl, C_1-6 haloalkyl, C_2-6 alkenyl, C2-6 alkynyl, CN, OR^a7, SR^a7, C(O)R^b7, C(O)NR^c7R^d7, C(O)OR^a7, OC(O)R^b7, OC(O)NR^c7R^d7, NR^c7R^d7, NR^c7C(O)R^b7, NR^c7C(O)NR^c7R^d7, NR^c7C(O)OR^a7, C(=NR^e7)NR^c7R^d7,

NR^c7C(=NR^e7)NR^c3R^d7, S(O)R^b7, S(O)NR^c7R^d7, S(O)2R^b7, NR^c7S(O)2R^b7, NR^c7S(O)2NR^c7R^d7, and S(O)₂NR^c7R^d7;

or R^c4 and R^d4 together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from CN, halo, C1-4 alkyl, C1-4 haloalkyl, C1-6 haloalkyl, C2-6 alkenyl, C_2-6 alkynyl, CN, OR^a7, SR^a7, C(O)R^b7, C(O)NR^c7R^d7, C(O)OR^a7, OC(O)R^b7, OC(O)NR^c7R^d7, NR^c7R^d7, NR^c7C(O)R^b7, NR^c7C(O)NR^c7R^d7, NR^c7C(O)OR^a7, C(=NR^e7)NR^c7R^d7,

NR^c7C(=NR^e7)NR^c3R^d7, S(O)R^b7, S(O)NR^c7R^d7, S(O)₂R^b7, NR^c7S(O)₂R^b7, NR^c7S(O)₂NR^c7R^d7, and S(O)2NR^c7R^d7;

or R^c5 and R^d5 together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from CN, halo, C1-4 alkyl, C1-4 haloalkyl, C1-6 haloalkyl, C2-6 alkenyl, C_2-6 alkynyl, CN, OR^a7, SR^a7, C(O)R^b7, C(O)NR^c7R^d7, C(O)OR^a7, OC(O)R^b7, OC(O)NR^c7R^d7, NR^c7R^d7, NR^c7C(O)R^b7, NR^c7C(O)NR^c7R^d7, NR^c7C(O)OR^a7, C(=NR^e7)NR^c7R^d7,

NR^c7C(=NR^e7)NR^c3R^d7, S(O)R^b7, S(O)NR^c7R^d7, S(O)₂R^b7, NR^c7S(O)₂R^b7, NR^c7S(O)₂NR^c7R^d7, and S(O)2NR^c7R^d7;

or R^c6 and R^d6 together with the N atom to which they are attached form a 4-7 membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from CN, halo, C_1-4 alkyl, C_1-4 haloalkyl, C_1-6 haloalkyl, C_2-6 alkenyl, C2-6 alkynyl, CN, OR^a7, SR^a7, C(O)R^b7, C(O)NR^c7R^d7, C(O)OR^a7, OC(O)R^b7, OC(O)NR^c7R^d7, NR^c7R^d7, NR^c7C(O)R^b7, NR^c7C(O)NR^c7R^d7, NR^c7C(O)OR^a7, C(=NR^e7)NR^c7R^d7,

NR^c7C(=NR^e7)NR^c3R^d7, S(O)R^b7, S(O)NR^c7R^d7, S(O)2R^b7, NR^c7S(O)2R^b7, NR^c7S(O)2NR^c7R^d7, and S(O)₂NR^c7R^d7;

R^a7, R^b7, R^c7, and R^d7 are independently selected from H, C1-6 alkyl, C1-6 haloalkyl, C2- ₆ alkenyl, C_2-6 alkynyl, C_6-10 aryl, C_3-7 cycloalkyl, 5-10 membered heteroaryl, 4-10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl- C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl, wherein said C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, C3-7 cycloalkyl, 5-10 membered heteroaryl, 4- 10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, C3-7 cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C_1-4 alkyl, and 4-10 membered heterocycloalkyl-C_1-4 alkyl are each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C_1-6 alkyl, C_1-6 alkoxy, C_1-6 haloalkyl, and C_1-6 haloalkoxy;

each R^e, R^e1, R^e3, R^e4, R^e5, R^e6 and R^e7 is independently selected from H, C1-4 alkyl, and CN;

a is 0 or 1;

b is 0, 1, 2, or 3;

c is 0, 1, or 2;

d is 0, 1, or 2;

m is 0 or 1;

n is 0 or 1;

p is 0 or 1;

q is 0 or 1;

r is 0 or 1;

t1 is 0 or 1;

t2 is 0 or 1;

t3 is 0 or 1;

u is 0, 1, 2, or 3; v is 0 or 1; and

w is 0 or 1;

wherein any aforementioned heteroaryl or heterocycloalkyl group comprises 1, 2, 3, or 4 ring-forming heteroatoms independently selected from O, N, and S; and

wherein one or more ring-forming C or N atoms of any aforementioned heterocycloalkyl group is optionally substituted by an oxo (=O) group. 257. The compound of any one of claims 1, 255 and 256, or a pharmaceutically acceptable salt thereof, wherein Q² is a compound having the formula B-2a:

258. The compound of any one of claims 1, 255 and 256, or a pharmaceutically acceptable salt thereof, wherein Q² is a compound having the formula B-2a:

wherein Z¹ and Z² are each independently selected from N and CH, and wherein R is CN, Cl, or CF3. 259. The compound of any one of claims 1, 255 and 256, or a pharmaceutically acceptable salt thereof, wherein Q³ is a compound having the formula B-3a:

260. The compound of any one of claims 1, 255 and 256, or a pharmaceutically acceptable salt thereof, wherein Q³ is a compound having the formula B-3b:

wherein Z¹ and Z² are each independently selected from N and CH, and wherein R is CN, Cl, or CF3.

261. The compound of any one of claims 1 and 255-260, or a pharmaceutically acceptable salt thereof, wherein X is Cl, Br, CH3, CF3, CN, OCH3, ethyl, cyclopropyl, SCH3, or isopropyl. 262. The compound of any one of claims 1 and 255-261, or a pharmaceutically acceptable salt thereof, wherein Ring E is a mono- or polycyclic ring selected from C_6-10 aryl, C_3-7 cycloalkyl, 5-10 membered heteroaryl, and 4-10 membered heterocycloalkyl. 263. The compound of any one of claims 1 and 255-261, or a pharmaceutically acceptable salt thereof, wherein Ring E is a mono- or polycyclic ring selected from C_6-10 aryl. 264. The compound of any one of claims 1 and 255-261, or a pharmaceutically acceptable salt thereof, wherein Ring E is a mono- or polycyclic ring selected from 5-10 membered heteroaryl. 265. The compound of any one of claims 1 and 255-261, or a pharmaceutically acceptable salt thereof, wherein Ring E is a mono- or polycyclic ring selected from C_3-7 cycloalkyl. 266. The compound of any one of claims 1 and 255-261, or a pharmaceutically acceptable salt thereof, wherein Ring E is a mono- or polycyclic ring selected from 4-10 membered heterocycloalkyl. 267. The compound of any one of claims 1 and 255-261, or a pharmaceutically acceptable salt thereof, wherein Ring E is phenyl. 268. The compound of any one of claims 1 and 255-261, or a pharmaceutically acceptable salt thereof, wherein Ring E is pyridinyl. 269. The compound of any one of claims 1 and 255-261, or a pharmaceutically acceptable salt thereof, wherein Ring E is cyclohexyl.

270. The compound of any one of claims 1 and 255-261, or a pharmaceutically acceptable salt thereof, wherein Ring E is pyridine-4(1H)-onyl, 4-pyridonyl, or piperidinyl 271. The compound of any one of claims 1 and 255-270, or a pharmaceutically acceptable salt thereof, wherein each R¹⁴ is independently selected from H, halo, OR^a4, and C1-6 alkyl, wherein said C_1-6 alkyl is optionally substituted with CN, OR^a7, NR^c4R^d4, or NR^c4C(O)R^b4. 272. The compound of any one of claims 1 and 255-270, or a pharmaceutically acceptable salt thereof, wherein each R¹⁴ is independently selected from halo, methyl, ethyl, and cyanomethyl, each optionally substituted with CN, OR^a7, NR^c4R^d4, or NR^c4C(O)R^b4. 273. The compound of any one of claims 1 and 255-272, or a pharmaceutically acceptable salt thereof, wherein each R¹⁵ is independently selected from H, halo, CN, NR^c4R^d4, OR^a4, C(O)R^b4, NRc4C(O)R^b4, C(O)NR^c4R^d4 and C_1-6 alkyl, wherein said C_1-6 alkyl is optionally substituted with CN, OR^a7, NR^c4R^d4, or NR^c4C(O)R^b4. 274. The compound of any one of claims 1 and 255-272, or a pharmaceutically acceptable salt thereof, wherein R¹⁵ is F or Cl. 275. The compound of any one of claims 1 and 255-272, or a pharmaceutically acceptable salt thereof, wherein each R¹⁵ is independently selected from halo and OR^a4. 276. The compound of any one of claims 1 and 255-272, or a pharmaceutically acceptable salt thereof, wherein each R¹⁵ is independently selected from halo and NR^c4R^d4. 277. The compound of any one of claims 1 and 255-272, or a pharmaceutically acceptable salt thereof, wherein each R¹⁵ is independently selected from halo, NR^c4C(O)R^b4, C(O)Rb4, and C(O)NR^c4R^d4. 278^. The compound of any one of claims 1 and 255-272, or a pharmaceutically acceptable salt thereof, wherein R¹⁵ is CN. 279. The compound of any one of claims 1 and 255-272, or a pharmaceutically acceptable salt thereof, wherein R¹⁵ is halo. 280. The compound of any one of claims 1 and 255-272, or a pharmaceutically acceptable salt thereof, wherein R¹⁵ is 4-10 membered heterocycloalkyl, optionally substituted with C_1-6 alkyl, NR^c4R^d4 or C(O)R^b4.

281. The compound of any one of claims 1 and 255-272, or a pharmaceutically acceptable salt thereof, wherein R¹⁵ is morpholinyl, piperidinyl, pyrrolidinyl, optionally substituted with OR^a4, NR^c4R^d4 or C(O)R^b4. 282. The compound of any one of claims 1 and 255-281, or a pharmaceutically acceptable salt thereof, wherein R^a4 is selected from C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, 4- 10 membered heterocycloalkyl, C6-10 aryl-C1-4 alkyl, cycloalkyl-C1-4 alkyl, 5-10 membered heteroaryl-C1-4 alkyl, and 4-10 membered heterocycloalkyl-C1-4 alkyl, each optionally substituted with C_1-4 alkyl, OR^a7, NR^c7R^d7, C(O)NR^c7R^d7, C(O)R^b7, C(O)OR^a7 or

NR^c7C(O)R^b7. 283. The compound of any one of claims 1 and 255-282, or a pharmaceutically acceptable salt thereof, wherein R^a4 is H or C_1-6 alkyl. 284. The compound of any one of claims 1 and 255-281, or a pharmaceutically acceptable salt thereof, wherein R^a4 is pyridinyl. 285. The compound of any one of claims 1 and 255-281, or a pharmaceutically acceptable salt thereof, wherein R^a4 is phenyl. 286. The compound of any one of claims 1 and 255-281, or a pharmaceutically acceptable salt thereof, wherein R^a4 is pyridinylmethyl, pyridinylethyl, tetrahydropyranylmethyl, tetrahydrofuranylmethyl, piperidinylmethyl, piperidinylethyl, morpholinylethyl, piperazinylethyl, pyrrolidinylmethyl. 287. The compound of any one of claims 1 and 255-281, or a pharmaceutically acceptable salt thereof, wherein R^a4 is methyl, ethyl, or isopropyl. 288. The compound of any one of claims 1 and 255-281, or a pharmaceutically acceptable salt thereof, wherein R^a4 is piperidinyl, tetrahydropyranyl, tetrahydrofuranyl, morpholinyl, pyrrolidinyl, each optionally substituted by an oxo (=O) group, C1-4 alkyl, OR^a7, NR^c7R^d7, C(O)NR^c7R^d7, C(O)R^b7, or NR^c7C(O)R^b7. 289. The compound of any one of claims 1 and 255-281, or a pharmaceutically acceptable salt thereof, wherein R^a4 is pyrimidinyl.

290. The compound of any one of claims 1 and 255-289, or a pharmaceutically acceptable salt thereof, wherein R^b4 is C_1-6 alkyl. 291. The compound of any one of claims 1 and 255-289, or a pharmaceutically acceptable salt thereof, wherein R^b4 is methyl. 292. The compound of any one of claims 1 and 255-291, or a pharmaceutically acceptable salt thereof, wherein R^c4 is H or C1-6 alkyl. 293. The compound of any one of claims 1 and 255-291, or a pharmaceutically acceptable salt thereof, wherein R^c4 is methyl. 294. The compound of any one of claims 1 and 255-293, or a pharmaceutically acceptable salt thereof, wherein R^d4 is H, C_1-6 alkyl, C_6-10 aryl, 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, 5-10 membered heteroaryl-C1-4 alkyl, 4-10 membered

heterocycloalkyl-C_1-4 alkyl, optionally substituted with 1, 2, 3, or 4 substituents independently selected from C1-6 alkyl, C(O)R^b7, and C(O)OR^a7. 295. The compound of any one of claims 1 and 255-293, or a pharmaceutically acceptable salt thereof, wherein R^d4 is methyl. 296. The compound of any one of claims 1 and 255-293, or a pharmaceutically acceptable salt thereof, wherein R^d4 is tetrehydrofuranylmethyl, pyridinylmethyl, pyridinylethyl, morpholinyl, piperidinyl, tetrahydropyranyl, or pyridinyl. 297. The compound of any one of claims 1 and 255-296, or a pharmaceutically acceptable salt thereof, wherein R^a7 is H or C1-6 alkyl. 298. The compound of any one of claims 1 and 255-296, or a pharmaceutically acceptable salt thereof, wherein R^a7 is methyl. 299. The compound of any one of claims 1 and 255-298, or a pharmaceutically acceptable salt thereof, wherein R^b7 is H or C_1-6 alkyl. 300. The compound of any one of claims 1 and 255-299, or a pharmaceutically acceptable salt thereof, wherein R^c7 is H or C1-6 alkyl.

301. The compound of any one of claims 1 and 255-300, or a pharmaceutically acceptable salt thereof, wherein R^d7 is H or C_1-6 alkyl. 302. The compound of any one of claims 1 and 255-301, or a pharmaceutically acceptable salt thereof, wherein R^b7 is H or methyl. 303. The compound of any one of claims 1 and 255-302, or a pharmaceutically acceptable salt thereof, wherein R^c7 is H or methyl. 304. The compound of any one of claims 1 and 255-303, or a pharmaceutically acceptable salt thereof, wherein R^d7 is H or methyl. 305. The compound of any one of claims 1 and 255-304, or a pharmaceutically acceptable salt thereof, wherein Y⁴ is O. 306. The compound of any one of claims 1 and 255-305, or a pharmaceutically acceptable salt thereof, wherein Y⁵ is O, NR^Y, C(=O), or C(=O)NR^Y. 307. The compound of any one of claims 1 and 255-306, or a pharmaceutically acceptable salt thereof, wherein G¹ is–C(R^G)(R^H)-. 308. The compound of any one of claims 1 and 255-307, or a pharmaceutically acceptable salt thereof, wherein G¹ is C-2. 309. The compound of any one of claims 1 and 255-308, or a pharmaceutically acceptable salt thereof, wherein D³, D⁴, and D⁵ are each CR^X, wherein each R^X is independently selected from H, halo, and C1-4 alkyl. 310. The compound of any one of claims 1 and 255-309, or a pharmaceutically acceptable salt thereof, wherein R^X is H. 311. The compound of any one of claims 1 and 255-310, or a pharmaceutically acceptable salt thereof, wherein G² is–C(R^I)(R^J)-. 312. The compound of any one of claims 1 and 255-310, or a pharmaceutically acceptable salt thereof, wherein G² is C-3. 313. The compound of any one of claims 1 and 255-312, or a pharmaceutically acceptable salt thereof, wherein D⁶, D⁷, and D⁹ are each CR^X, and D⁸ is N.

314. The compound of any one of claims 1 and 255-312, or a pharmaceutically acceptable salt thereof, wherein D⁶ and D⁷ are each N, and D⁸ and D⁹ are each CR^X. 315. The compound of any one of claims 1 and 255-312, or a pharmaceutically acceptable salt thereof, wherein D⁶, D⁷, D⁸, and D⁹ are each CR^X. 316. The compound of any one of claims 1 and 255-312, or a pharmaceutically acceptable salt thereof, wherein D⁶, D⁸, and D⁹ are each CR^X, and D⁷ is N. 317. The compound of any one of claims 1 and 255-312, or a pharmaceutically acceptable salt thereof, wherein D⁶, D⁷, and D⁸ are each CR^X and D⁹ is N. 318. The compound of any one of claims 1 and 255-312, or a pharmaceutically acceptable salt thereof, wherein D⁶ and D⁸ are each N, and D⁷ and D⁹ are each CR^X. 319. The compound of any one of claims 1 and 255-312, or a pharmaceutically acceptable salt thereof, wherein D⁶ and D⁹ are each N, and D⁷ and D⁸ are each CR^X. 320. The compound of any one of claims 1 and 255-319, or a pharmaceutically acceptable salt thereof, wherein G² is C-1. 321. The compound of any one of claims 1 and 255-320 or a pharmaceutically acceptable salt thereof, wherein D¹ and D² are each N and D¹⁰ is CH₂. 322. The compound of any one of claims 1 and 255-321, or a pharmaceutically acceptable salt thereof, wherein b is 0, c is 1, and d is 1. 323. The compound of any one of claims 1 and 255-322, or a pharmaceutically acceptable salt thereof, wherein Ring F is 4-10 membered heterocycloalkyl, 5-10 membered heteroaryl, or C3-7 cycloalkyl, each optionally substituted with C1-6 alkyl, wherein said C1-6 alkyl is optionally substituted with OR^a6. 324. The compound of any one of claims 1 and 255-323, or a pharmaceutically acceptable salt thereof, wherein Ring F is 4-10 membered heterocycloalkyl or C3-7 cycloalkyl, each optionally substituted with methyl. 325. The compound of any one of claims 1 and 255-323, or a pharmaceutically acceptable salt thereof, wherein Ring F is piperazinyl, piperidinyl, pyrrolidinyl, pyridinyl, 5,6,7,8- tetrahydro-[1,2,4]triazolo[4,3-a]pyrazinyl, 2,8-diazaspiro[4.5]decanyl, 2,5- diazabicyclo[2.2.2]octanyl, 1,4-diazepanyl, azetidinyl, 2,6-diazaspiro[3.3]heptanyl, 2,6- diazaspiro[3.4]octanyl, octahydropyrrolo[3,2-b]pyrrolyl, 2,7-diazaspiro[4.4]nonanyl, 2,5- diazabicyclo[2.2.1]heptanyl, octahydropyrrolo[3,4-c]pyrrolyl, 2,7-diazaspiro[3.5]nonanyl, or 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine. 326. The compound of any one of claims 1 and 255-323, or a pharmaceutically acceptable salt thereof, wherein Ring F is piperzinyl. 327. The compound of any one of claims 1 and 255-323, or a pharmaceutically acceptable salt thereof, wherein Ring F is cyclohexyl. 328. The compound of any one of claims 1 and 255-323, or a pharmaceutically acceptable salt thereof, wherein Ring F is 4-10 membered heterocycloalkyl, optionally substituted by an oxo (=O) group. 329. The compound of any one of claims 1 and 255-328, or a pharmaceutically acceptable salt thereof, wherein Z is Cy^Z, CN, C_1-6 alkyl, or C(O)R^b, wherein said C_1-6 alkyl is optionally substituted by halo. 330. The compound of any one of claims 1 and 255-328, or a pharmaceutically acceptable salt thereof, wherein Z is CF3, CH3, or CN. 331. The compound of any one of claims 1 and 255-328, or a pharmaceutically acceptable salt thereof, wherein Z is H. 332. The compound of any one of claims 1 and 255-331, or a pharmaceutically acceptable salt thereof, wherein R^b is C_1-6 alkyl, optionally substituted with CN. 333. The compound of any one of claims 1 and 255-331, or a pharmaceutically acceptable salt thereof, wherein R^b is methyl. 334. The compound of any one of claims 1 and 255-333, or a pharmaceutically acceptable salt thereof, wherein Cy^Z is selected from 5-10 membered heteroaryl and C6-10 aryl, each optionally substituted by C_1-6 alkyl, halo, CN or CF₃, wherein said C_1-6 alkyl is optionally substituted with CN.

335. The compound of any one of claims 1 and 255-333, or a pharmaceutically acceptable salt thereof, wherein Cy^Z is pyridinyl, pyrimidinyl, or pyrazinyl, each optionally substituted by C1-6 alkyl, CN, Cl, F, S(O)2R^b1, or CF3. 336. The compound of any one of claims 1 and 255-333, or a pharmaceutically acceptable salt thereof, wherein Cy^Z is pyridinyl, pyrimidinyl, pyrazinyl, each optionally substituted by methyl, CN, Cl, F, CF3, or S(O)2CH3. 337. The compound of any one of claims1 and 255-333, or a pharmaceutically acceptable salt thereof, wherein Cy^Z is phenyl, optionally substituted with cyanomethyl or CN. 338. The compound of any one of claims 1 and 255-337, or a pharmaceutically acceptable salt thereof, wherein R^b1 is C1-6 alkyl. 339. The compound of any one of claims 1 and 255-337, or a pharmaceutically acceptable salt thereof, wherein R^b1 is methyl. 340. The compound of any one of claims 1 and 255-339, or a pharmaceutically acceptable salt thereof, wherein R^A is H, halo, OR^a5, C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C1-4 alkyl, wherein said C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C_1-4 alkyl is optionally substituted with OR^a5 or NR^c5R^d5. 341. The compound of any one of claims 1 and 255-339, or a pharmaceutically acceptable salt thereof, wherein R^A is C1-6 alkyl or H. 342. The compound of any one of claims 1 and 255-339, or a pharmaceutically acceptable salt thereof, wherein R^A is methyl. 343. The compound of any one of claims 1 and 255-339, or a pharmaceutically acceptable salt thereof, wherein R^A is H. 344. The compound of any one of claims 1 and 255-343, or a pharmaceutically acceptable salt thereof, wherein R^B is H, halo, OR^a5, C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C1-4 alkyl, wherein said C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C_1-4 alkyl is optionally substituted with OR^a5 or NR^c5R^d5. 345. The compound of any one of claims 1 and 255-343, or a pharmaceutically acceptable salt thereof, wherein R^B is C1-6 alkyl or H.

346. The compound of any one of claims 1 and 255-343, or a pharmaceutically acceptable salt thereof, wherein R^B is methyl. 347. The compound of any one of claims 1 and 255-343, or a pharmaceutically acceptable salt thereof, wherein R^B is H. 348. The compound of any one of claims 1 and 255-347, or a pharmaceutically acceptable salt thereof, wherein R^C is H, halo, OR^a5, C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C_6-10 aryl-C_1-4 alkyl, wherein said C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C_6-10 aryl-C1-4 alkyl is optionally substituted with OR^a5 or NR^c5R^d5. 349. The compound of any one of claims 1 and 255-347, or a pharmaceutically acceptable salt thereof, wherein R^C is C1-6 alkyl or H. 350. The compound of any one of claims 1 and 255-347, or a pharmaceutically acceptable salt thereof, wherein R^C is methyl. 351. The compound of any one of claims 1 and 255-347, or a pharmaceutically acceptable salt thereof, wherein R^C is H. 352. The compound of any one of claims 1 and 255-351, or a pharmaceutically acceptable salt thereof, wherein R^D is H, halo, OR^a5, C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C_6-10 aryl-C_1-4 alkyl, wherein said C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C_6-10 aryl-C1-4 alkyl is optionally substituted with OR^a5 or NR^c5R^d5. 353. The compound of any one of claims 1 and 255-351, or a pharmaceutically acceptable salt thereof, wherein R^D is C1-6 alkyl or H. 354. The compound of any one of claims 1 and 255-351, or a pharmaceutically acceptable salt thereof, wherein R^D is methyl. 355. The compound of any one of claims 1 and 255-351, or a pharmaceutically acceptable salt thereof, wherein R^D is H. 356. The compound of any one of claims 1 and 255-355, or a pharmaceutically acceptable salt thereof, wherein R^E is H, halo, OR^a5, C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C_6-10 aryl-C_1-4 alkyl, wherein said C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C_6-10 aryl-C1-4 alkyl is optionally substituted with OR^a5 or NR^c5R^d5.

357. The compound of any one of claims 1 and 255-355, or a pharmaceutically acceptable salt thereof, wherein R^E is C_1-6 alkyl or H. 358. The compound of any one of claims 1 and 255-355, or a pharmaceutically acceptable salt thereof, wherein R^E is methyl. 359. The compound of any one of claims 1 and 255-355, or a pharmaceutically acceptable salt thereof, wherein R^E is H. 360. The compound of any one of claims 1 and 255-359, or a pharmaceutically acceptable salt thereof, wherein R^F is H, halo, OR^a5, C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C1-4 alkyl, wherein said C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C1-4 alkyl is optionally substituted with OR^a5 or NR^c5R^d5. 361. The compound of any one of claims 1 and 255-359, or a pharmaceutically acceptable salt thereof, wherein R^F is C_1-6 alkyl or H. 362. The compound of any one of claims 1 and 255-359, or a pharmaceutically acceptable salt thereof, wherein R^F is methyl. 363. The compound of any one of claims 1 and 255-359, or a pharmaceutically acceptable salt thereof, wherein R^F is H. 364. The compound of any one of claims 1 and 255-363, or a pharmaceutically acceptable salt thereof, wherein R^G is H, halo, OR^a5, C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C_6-10 aryl-C_1-4 alkyl, wherein said C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C_6-10 aryl-C1-4 alkyl is optionally substituted with OR^a5 or NR^c5R^d5. 365. The compound of any one of claims 1 and 255-363, or a pharmaceutically acceptable salt thereof, wherein R^G is C_1-6 alkyl or H. 366. The compound of any one of claims 1 and 255-363, or a pharmaceutically acceptable salt thereof, wherein R^G is methyl. 367. The compound of any one of claims 1 and 255-363, or a pharmaceutically acceptable salt thereof, wherein R^G is H.

368. The compound of any one of claims 1 and 255-367, or a pharmaceutically acceptable salt thereof, wherein R^H is H, halo, OR^a5, C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C1-4 alkyl, wherein said C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C_1-4 alkyl is optionally substituted with OR^a5 or NR^c5R^d5. 369. The compound of any one of claims 1 and 255-367, or a pharmaceutically acceptable salt thereof, wherein R^H is C1-6 alkyl or H. 370. The compound of any one of claims 1 and 255-367, or a pharmaceutically acceptable salt thereof, wherein R^H is methyl. 371. The compound of any one of claims 1 and 255-367, or a pharmaceutically acceptable salt thereof, wherein R^H is H. 372. The compound of any one of claims 1 and 255-371, or a pharmaceutically acceptable salt thereof, wherein R^I is H, halo, OR^a5, C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C1-4 alkyl, wherein said C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C_1-4 alkyl is optionally substituted with OR^a5 or NR^c5R^d5. 373. The compound of any one of claims 1 and 255-371, or a pharmaceutically acceptable salt thereof, wherein R^I is C_1-6 alkyl or H. 374. The compound of any one of claims 1 and 255-371, or a pharmaceutically acceptable salt thereof, wherein R^I is methyl. 375. The compound of any one of claims 1 and 255-371, or a pharmaceutically acceptable salt thereof, wherein R^I is H. 376. The compound of any one of claims 1 and 255-375, or a pharmaceutically acceptable salt thereof, wherein R^J is H, halo, OR^a5, C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C1-4 alkyl, wherein said C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C1-4 alkyl is optionally substituted with OR^a5 or NR^c5R^d5. 377. The compound of any one of claims 1 and 255-375, or a pharmaceutically acceptable salt thereof, wherein R^J is C_1-6 alkyl or H. 378. The compound of any one of claims 1 and 255-375, or a pharmaceutically acceptable salt thereof, wherein R^J is methyl.

379. The compound of any one of claims 1 and 255-375, or a pharmaceutically acceptable salt thereof, wherein R^J is H. 380. The compound of any one of claims 1 and 255-379, or a pharmaceutically acceptable salt thereof, wherein R^K is H, halo, OR^a5, C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C_6-10 aryl-C_1-4 alkyl, wherein said C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C_6-10 aryl-C1-4 alkyl is optionally substituted with OR^a5 or NR^c5R^d5. 381. The compound of any one of claims 1 and 255-379, or a pharmaceutically acceptable salt thereof, wherein R^K is C1-6 alkyl or H. 382. The compound of any one of claims 1 and 255-379, or a pharmaceutically acceptable salt thereof, wherein R^K is methyl. 383. The compound of any one of claims 1 and 255-379, or a pharmaceutically acceptable salt thereof, wherein R^K is H. 384. The compound of any one of claims 1 and 255-383, or a pharmaceutically acceptable salt thereof, wherein R^L is H, halo, OR^a5, C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C1-4 alkyl, wherein said C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C_1-4 alkyl is optionally substituted with OR^a5 or NR^c5R^d5. 385. The compound of any one of claims 1 and 255-383, or a pharmaceutically acceptable salt thereof, wherein R^L is C1-6 alkyl or H. 386. The compound of any one of claims 1 and 255-383, or a pharmaceutically acceptable salt thereof, wherein R^L is methyl. 387. The compound of any one of claims 1 and 255-383, or a pharmaceutically acceptable salt thereof, wherein R^L is H. 388. The compound of any one of claims 1 and 255-387, or a pharmaceutically acceptable salt thereof, wherein R^M is H, halo, OR^a5, C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C1-4 alkyl, wherein said C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C6-10 aryl-C_1-4 alkyl is optionally substituted with OR^a5 or NR^c5R^d5. 389. The compound of any one of claims 1 and 255-387, or a pharmaceutically acceptable salt thereof, wherein R^M is C1-6 alkyl or H.

390. The compound of any one of claims 1 and 255-387, or a pharmaceutically acceptable salt thereof, wherein R^M is methyl. 391. The compound of any one of claims 1 and 255-387, or a pharmaceutically acceptable salt thereof, wherein R^M is H. 392. The compound of any one of claims 1 and 255-391, or a pharmaceutically acceptable salt thereof, wherein R^N is H, halo, OR^a5, C1-6 alkyl, C6-10 aryl, 5-10 membered heteroaryl, or C_6-10 aryl-C_1-4 alkyl, wherein said C_1-6 alkyl, C_6-10 aryl, 5-10 membered heteroaryl, or C_6-10 aryl-C1-4 alkyl is optionally substituted with OR^a5 or NR^c5R^d5. 393. The compound of any one of claims 1 and 255-391, or a pharmaceutically acceptable salt thereof, wherein R^N is C1-6 alkyl or H. 394. The compound of any one of claims 1 and 255-391, or a pharmaceutically acceptable salt thereof, wherein R^N is methyl. 395. The compound of any one of claims 1 and 255-391, or a pharmaceutically acceptable salt thereof, wherein R^N is H. 396. The compound of any one of claims 1 and 255-395, or a pharmaceutically acceptable salt thereof, wherein R^K and R^M together form a double bond between the carbon atoms to which they are attached. 397. The compound of any one of claims 1 and 255-395, or a pharmaceutically acceptable salt thereof, wherein R^I and R^K together form a double bond between the carbon atoms to which they are attached 398. The compound of any one of claims 1 and 255-397, or a pharmaceutically acceptable salt thereof, wherein each R^X is H or halo. 399. The compound of any one of claims 1 and 255-397, or a pharmaceutically acceptable salt thereof, wherein R^X is H. 400. The compound of any one of claims 1 and 255-397, or a pharmaceutically acceptable salt thereof, wherein R^X is F

401. The compound of any one of claims 1 and 255-400, or a pharmaceutically acceptable salt thereof, wherein Y⁶ is C(=O), NR^Y, or C(=O)NR^Y. 402. The compound of any one of claims 1 and 255-401, or a pharmaceutically acceptable salt thereof, wherein R^Y is H or C1-4 alkyl. 403. The compound of any one of claims 1 and 255-401, or a pharmaceutically acceptable salt thereof, wherein R^Y is H. 404. The compound of any one of claims 1 and 255-401, or a pharmaceutically acceptable salt thereof, wherein R^Y is methyl. 405. The compound of any one of claims 1 and 255-401, or a pharmaceutically acceptable salt thereof, wherein t1 is 0. 406. The compound of any one of claims 1 and 255-405 or a pharmaceutically acceptable salt thereof, wherein t1 is 1. 407. The compound of any one of claims 1 and 255-406, or a pharmaceutically acceptable salt thereof, wherein t2 is 0. 408. The compound of any one of claims 1 and 255-407, or a pharmaceutically acceptable salt thereof, wherein t3 is 0. 409. The compound of any one of claims 1 and 255-408, or a pharmaceutically acceptable salt thereof, wherein u is 0. 410. The compound of any one of claims 1 and 255-408, or a pharmaceutically acceptable salt thereof, wherein u is 1. 411. The compound of any one of claims 1 and 255-408, or a pharmaceutically acceptable salt thereof, wherein u is 2. 412. The compound of any one of claims 1 and 255-411, or a pharmaceutically acceptable salt thereof, wherein a is 0. 413. The compound of any one of claims 1 and 255-412, or a pharmaceutically acceptable salt thereof, wherein t2 is 1.

414. The compound of any one of claims 1 and 255-413, or a pharmaceutically acceptable salt thereof, wherein t3 is 1. 415. The compound of any one of claims 1 and 255-414, or a pharmaceutically acceptable salt thereof, wherein v is 0. 416. The compound of any one of claims 1 and 255-414, or a pharmaceutically acceptable salt thereof, wherein v is 1. 417. The compound of any one of claims 1 and 255-416, or a pharmaceutically acceptable salt thereof, wherein w is 0. 418. The compound of any one of claims 1 and 255-416, or a pharmaceutically acceptable salt thereof, wherein w is 1. 419. The compound of any one of claims 1 and 255-418, or a pharmaceutically acceptable salt thereof, wherein m is 0. 420. The compound of any one of claims 1 and 255-418, or a pharmaceutically acceptable salt thereof, wherein m is 1. 421. The compound of any one of claims 1 and 255-420, or a pharmaceutically acceptable salt thereof, wherein n is 0. 422. The compound of any one of claims 1 and 255-420, or a pharmaceutically acceptable salt thereof, wherein n is 1. 423. The compound of any one of claims 1 and 255-422, or a pharmaceutically acceptable salt thereof, wherein p is 0. 424. The compound of any one of claims 1 and 255-422, or a pharmaceutically acceptable salt thereof, wherein p is 1. 425. The compound of any one of claims 1 and 255-424, or a pharmaceutically acceptable salt thereof, wherein q is 0. 426. The compound of any one of claims 1 and 255-424, or a pharmaceutically acceptable salt thereof, wherein q is 1.

427. The compound of any one of claims 1 and 255-426, or a pharmaceutically acceptable salt thereof, wherein r is 1. 428. The compound of any one of claims 1 and 255-427, or a pharmaceutically acceptable salt thereof, having Formula IVa:

429. The compound of any one of claims 1 and 255-427, or a pharmaceutically acceptable salt thereof, having Formula IVb:

IVb. 430. The compound of any one of claims 1 and 255-427, or a pharmaceutically acceptable salt thereof, having Formula IVc:

IVc. 431. The compound of any one of claims 1 and 255-427, or a pharmaceutically acceptable salt thereof, having Formula IVd:

IVd. 432. The compound of any one of claims 1 and 255-427, or a pharmaceutically acceptable salt thereof, having Formula IVe:

IVe.

433. The compound of claim 1, wherein the compound is 5-[[(2S)-1-(3-oxo-3-[4-[5- (trifluoromethyl)pyrimidin-2-yl]piperazin-1-yl]propoxy)propan-2-yl]amino]-4- (trifluoromethyl)-2,3-dihydropyridazin-3-one, or a pharmaceutically acceptable salt thereof. 434. The compound of claim 433, wherein the compound is crystalline. 435. The compound of claim 433 or 434, wherein the compound has at least one characteristic XRPD peak selected from about 5.8, about 10.8, about 11.9, and about 17.2 degrees 2-theta.

436. The compound of claim 433 or 434, wherein the compound has at least one characteristic XRPD peak selected from about 5.8, about 10.8, about 11.9, about 13.3, about 13.5, about 15.5, and about 17.2 degrees 2-theta. 437. The compound of claim 433 or 434, wherein the compound has an XRPD pattern with characteristic peaks as substantially shown in Figure 8. 438. The compound of any one of claims 433-437, wherein the compound has a DSC thermogram characterized by having an endothermic peak at a temperature of about 174 ºC. 439. The compound of any one of claims 433-437, wherein the compound has a DSC thermogram substantially as depicted in Figure 9. 440. A pharmaceutical composition comprising a compound of any one of claims 1 to 439, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier. 441. A method of inhibiting the activity of PARP7 comprising contacting a compound of any one of claims 1 to 439, or a pharmaceutically acceptable salt thereof, with said PARP7. 442. A method of treating cancer in a patient in need of treatment comprising

administering to said patient a therapeutically effective amount of a compound of any one of claims 1 to 439, or a pharmaceutically acceptable salt thereof. 443. The method of claim 442 wherein said cancer is breast cancer, cancer of the central nervous system, endometrium cancer, kidney cancer, large intestine cancer, lung cancer, oesophagus cancer, ovarian cancer, pancreatic cancer, prostate cancer, stomach cancer, head and neck cancer (upper aerodigestive cancer), urinary tract cancer, or colon cancer.